# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001654954-25-012630
**Filing Date:** 2025-11
**Character Count:** 137252
**Document Hash:** 37eac2f0acafc09f1cfc4d0682486ecd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-012630.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001654954-25-012630

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251106

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 251456192

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

 **FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-11960

 **AstraZeneca PLC**

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

 **AstraZeneca PLC**

INDEX TO EXHIBITS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

 ***1.***

 ***9M and Q3 2025 results***

6 November 2025

AstraZeneca results: 9M and Q3 2025

 **Continued strong commercial performance and unprecedented pipeline delivery in the year to date**

Revenue and EPS summary

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | | **% Change** | **% Change** | | **% Change** | **% Change** |
|  | **9M 2025**<br>**$m**  | **Actual**  | **CER**<sup>1</sup> | **Q3 2025**<br>**$m**  | **Actual**  | **CER** |
| *- Product Sales* | *41035*  | *9*  | *9*  | *14365*  | *11*  | *9*  |
| *- Alliance Revenue* | *2108*  | *41*  | *41*  | *815*  | *46*  | *44*  |
| Product Revenue<sup>2</sup> | 43143  | 10  | 11  | 15180  | 12  | 11  |
| Collaboration Revenue | 93  | (14) | (15) | 11  | (81) | (82) |
| **Total Revenue** | **43236**  | **10**  | **11**  | **15191**  | **12**  | **10**  |
| **Reported EPS ($)** | **5.10**  | **43**  | **42**  | **1.64**  | **77**  | **70**  |
| **Core**<sup>3</sup> **EPS ($)** | **7.04**  | **15**  | **15**  | **2.38**  | **14**  | **12**  |

---

 <u>Key performance elements for 9M 2025</u>

(Growth numbers at constant exchange rates)

● Total Revenue up 11% to $43,236m, driven by growth in all Therapy Areas, including 16% growth in Oncology and 13% growth in R&I

● Growth in Total Revenue across all major geographic regions

● Core Operating profit increased 13%

● Core EPS increased 15% to $7.04

● 16 positive Phase III readouts and 31 approvals in major regions

 <u>Pascal Soriot, Chief Executive Officer, AstraZeneca, said:</u>

"The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition.

Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and Enhertu and Datroway in breast cancer.

We are also delivering on our strategy to strengthen our operations in the United States to power our growth. This includes a historic agreement with the US government to lower the cost of medicines for American patients, and broadening our US manufacturing footprint having broken ground at our new $4.5bn Virginia manufacturing facility in October."

 <u>Guidance</u>

AstraZeneca reiterates its Total Revenue and Core EPS guidance<sup>4</sup> for FY 2025 at CER, based on the average foreign exchange rates through 2024.

 **Total Revenue** is expected to increase by a **high single-digit** percentage

 **Core EPS** is expected to increase by a **low double-digit** percentage

The Core Tax rate is expected to be between 18-22%

If foreign exchange rates for October 2025 to December 2025 were to remain at the average rates seen in September 2025, it is anticipated that FY 2025 Total Revenue growth and Core EPS growth would be broadly similar to the growth at CER (unchanged from the previous guidance).

<u>http://www.rns-pdf.londonstockexchange.com/rns/3923G_1-2025-11-5.pdf</u>

Results highlights

Table 1. Milestones achieved since the prior results announcement

Phase III and other registrational data readouts

---

| | | | |
|:---|:---|:---|:---|
| **Medicine** | **Trial** | **Indication** | **Event** |
| *Enhertu* | DESTINY-Breast05 | High-risk HER2+ early breast cancer (post-neoadjuvant) | Primary endpoint met |
| *Datroway* | TROPION-Breast02 | 1L TNBC for patients where IO is not an option | Dual primary endpoints met |
| *Imfinzi* | MATTERHORN | Resectable gastric/GEJ cancer | Secondary endpoint met (OS) |
| baxdrostat | Bax24 | Treatment resistant hypertension | Primary endpoint met |
| *Fasenra* | RESOLUTE | COPD | Primary endpoint not met |
| *Saphnelo* | TULIP-SC | SLE (subcutaneous) | Primary endpoint met |

---

Regulatory approvals

---

| | | | |
|:---|:---|:---|:---|
| **Medicine** | **Trial** | **Indication** | **Region** |
| *Calquence* | ECHO | 1L MCL | JP |
| *Calquence* | ACE-LY-004 | Relapsed/refractory MCL | JP |
| *Datroway* | TROPION-Breast01 | HR+ HER2- mBC | CN |
| *Enhertu* | DESTINY-Breast06 | CTx naïve HER2-low and - ultralow mBC | JP |
| *Imfinzi* | NIAGARA | Bladder cancer | JP |
| *Imfinzi* | AEGEAN | Resectable NSCLC | JP |
| *Lynparza* | PROpel | BRCAm mCRPC | CN |
| *Tezspire* | WAYPOINT | Chronic rhinosinusitis with nasal polyps | US, EU |
| *Koselugo* | KOMET | Adult neurofibromatosis type 1 | JP, EU |
| *Ultomiris* | CHAMPION-NMOSD | NMOSD | CN |

---

Regulatory submissions or acceptances\* in major regions

---

| | | | |
|:---|:---|:---|:---|
| **Medicine** | **Trial** | **Indication** | **Region** |
| *Enhertu* | DESTINY-PanTumour02 | Previously treated HER2+ solid tumours | EU |
| *Enhertu* | DESTINY-Gastric04 | 2L HER2+ gastric/GEJ cancer | EU |
| *Enhertu* | DESTINY-Breast09 | 1L HER2+ mBC | US, JP, CN |
| *Enhertu* | DESTINY-Breast11 | Neoadjuvant HER2+ Stage II or III breast cancer | US, CN |
| *Imfinzi* | MATTERHORN | Resectable early-stage gastric and GEJ cancers | EU, JP |
| *Imfinzi* | POTOMAC | High-risk non-muscle invasive bladder cancer | US, EU, JP |
| *Truqap* | CAPItello-281 | PTEN-deficient metastatic hormone-sensitive prostate cancer | US, EU |
| *Breztri* | KALOS/LOGOS | Uncontrolled asthma | US, EU, JP, CN |
| *Fasenra* | NATRON | HES | US, EU, JP, CN |
| *Saphnelo* | TULIP-SC | SLE (subcutaneous) | US, EU, JP |
| *Saphnelo* | TULIP-1/2, AZALEA | SLE | CN |
| *gefurulimab* | PREVAIL | Generalised myasthenia gravis | JP |

---

 *\* US, EU and China regulatory submissions denotes filing acceptance*

 <u>Other pipeline updates</u>

For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on <u>www.astrazeneca.com/investor-relations.html</u>.

Table 2: Key elements of financial performance: Q3 2025

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| For the **quarter** | **Reported**  | **Change** | **Change** | **Core**  | **Change** | **Change** |  |
| ended 30 September | **$m**  | **Act** | **CER** | **$m**  | **Act** | **CER** |  |
| Product Revenue | 15180  | 12  | 11  | 15180  | 12  | 11  | ∗See Tables 3, 27 and 28 for medicine details of Product Revenue, Product Sales and Alliance Revenue |
| Collaboration Revenue | 11  | (81) | (82) | 11  | (81) | (82) | ∗See Tables 4 and 29 for details of Collaboration Revenue |
| Total Revenue<br>| 15191  | 12  | 10  | 15191  | 12  | 10  | ∗See Tables 5 and 6 for Total Revenue by Therapy Area and by region |
| Gross Margin (%) | 82  | +4pp  | +4pp  | 82  | -  | -  | ∗Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue<br> ∗See 'Reporting changes' below for the definition of Gross Margin<sup>5</sup> |
| R&D expense | 3663  | 18  | 16  | 3550  | 16  | 14  | &nbsp;&nbsp;&nbsp; ∗Core R&D: 23% of Total Revenue<br> + Accelerated recruitment year-to-date in ongoing trials<br> + Investments in transformative technologies such as IO bispecifics, cell therapy and radioconjugates<br> + Positive data read-outs for high-value pipeline opportunities that have ungated large late-stage trials<br> + Addition of R&D projects from business development |
| SG&A expense | 5085 | (1) | (3) | 3822  | 6  | 4  | ∗Core SG&A: 25% of Total Revenue |
| Other operating income and expense<sup>6</sup> | 89  | >3x  | >3x  | 96  | >3x  | >3x  |  |
| Operating Profit | 3583  | 70  | 64  | 4993  | 16  | 13  |  |
| Operating Margin (%) | 24  | +8pp  | +8pp  | 33  | +1pp  | +1pp  |  |
| Net finance expense | 349  | 27  | 25  | 305  | (7)  | (9) | &nbsp;&nbsp;&nbsp; - Reduction in Core driven by lower short-term borrowing during the quarter<br> + Reported expense in Q3 2024 included a favourable fair value adjustment |
| Tax rate (%) | 22  | -  | -  | 21  | +2pp | +2pp | ∗Variations in the tax rate can be expected between periods |
| EPS ($) | 1.64  | 77  | 70  | 2.38  | 14  | 12  |  |

---

 *For monetary values the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).*

 *In the expense commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a '+' symbol beside an R&D expense comment indicates that the item increased R&D expenditure relative to the prior year period.*

 <u>Corporate and business development</u>

Listing harmonisation

As announced on 29 September 2025 and approved by shareholders on 3 November 2025, AstraZeneca will harmonise its share listing structure to deliver a global listing for global investors in a global company. It is expected that AstraZeneca shareholders will be able to trade their interests in AstraZeneca ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange from 2 February 2026. For further details, see the <u>Circular</u> containing details of the Harmonised Listing Structure.

US investment plans

In October 2025, AstraZeneca announced having broken ground on its $4.5bn manufacturing facility in Rivanna Futures, Albemarle County, Virginia. This is part of the Company's plans to invest $50bn in US manufacturing and R&D by 2030, announced in July 2025.

The Virginia plant is expected to create approximately 3,600 direct and indirect jobs. It will produce drug substance for AstraZeneca's weight management and metabolic portfolio, including oral GLP-1 (AZD5004), baxdrostat, oral PCSK9 (laroprovstat) and combination small molecule products, and also antibody drug conjugates for the Oncology portfolio.

Agreement with US Government

In October 2025, AstraZeneca announced a historic agreement with the US administration to lower the cost of prescription medicines for American patients. The Company voluntarily agreed to a range of measures which will enable American patients to access medicines at prices that are equalised with those available in wealthy countries.

As part of the agreement, AstraZeneca will provide Direct-to-Consumer sales to eligible patients with prescriptions for select products for chronic diseases.

AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America.

SixPeaks

On 22 October 2025, AstraZeneca, by exercise of an option, completed the acquisition of the remaining share capital of SixPeaks Bio AG (SixPeaks), following an initial investment of $15m made in Q2 2024. $170m was paid on closing, $30m to be paid after two years and up to a further $100m is payable on achievement of regulatory milestones. SixPeaks is investigating potential therapies for weight-management with the aim of preserving lean muscle mass.

Agreement with Merck on *Koselugo*

In August 2025, the contractual arrangements between AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) were updated and simplified relating to the global development and commercialisation of *Koselugo*, an oral, selective MEK inhibitor. Under the updated arrangements AstraZeneca will fully recognise the costs, revenues and profits of *Koselugo* globally. Merck received an upfront payment of $150 million and will receive deferred payments totalling up to $400m. In addition, Merck is eligible to receive up to $175m in potential approval milestones and up to $235m in sales milestone payments, plus single-digit royalties based on net sales. Prior to the updated arrangements, AstraZeneca fully recognised the revenues of *Koselugo* but shared equally pre-tax profits and losses of the product with Merck.

 <u>Sustainability highlights</u>

For the third consecutive year, TIME Magazine recognised AstraZeneca as one of the World's Best Companies with the Company ranking at 43 out of 1,000 global companies and as the top pharmaceutical company in terms of sustainability transparency.

 <u>Reporting calendar</u>

The Company intends to publish its FY and Q4 2025 results on 10 February 2026.

 <u>Conference call</u>

A conference call and webcast for investors and analysts will begin today, 6 November 2025, at 13:00 UK time. Details can be accessed via astrazeneca.com.

 <u>Reporting changes since FY 2024</u>

Product Revenue

Effective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal 'Product Revenue' representing the summation of Product Sales and Alliance Revenue.

Product Revenue and Collaboration Revenue form Total Revenue.

Product Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue.

Full descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group's <u>Annual Report and Form 20-F Information 2024.</u>

Gross Margin

Effective 1 January 2025, the Group has replaced the measure of 'Product Sales Gross Margin' with the measure of 'Gross Margin'. Previously, the measure excluded margin related to Alliance Revenue and Collaboration Revenue. The new measure is calculated using Gross profit as a percentage of Total Revenue, thereby encompassing all revenue categories, and is intended to provide a more comprehensive measure of total performance.

 <u>Notes</u>

1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2025 vs. 2024. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.

2. Effective 1 January 2025, the Group has updated its presentation of Total Revenue, adding a new subtotal of Product Revenue, the sum of Product Sales and Alliance Revenue. For further details, see Note 1: 'Basis of preparation and accounting policies' in the Notes to the Interim Financial Statements.

3. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 9 and 10 in the Financial Performance section of this document.

4. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.

5. Effective 1 January 2025, the Group has updated its presentation of Gross Margin. For further details, see Note 1: 'Basis of preparation and accounting policies' in the Notes to the Interim Financial Statements.

6. Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group's financial statements.

Revenue drivers

Table 3: Product Revenue by medicine

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | **% Change** | **% Change** | | | **% Change** | **% Change** |
|  | **9M 2025** <br>**$m**  | <br> **% Total**  | **Actual**  | **CER**  | **Q3 2025** <br>**$m**  | <br> **% Total**  | **Actual**  | **CER**  |
| *Tagrisso* | 5352  | 12  | 10  | 10  | 1864  | 12  | 11  | 10  |
| *Imfinzi* | 4317  | 10  | 25  | 25  | 1601  | 11  | 33  | 31  |
| *Calquence* | 2551  | 6  | 10  | 10  | 916  | 6  | 13  | 11  |
| *Lynparza* | 2401  | 6  | 8  | 7  | 837  | 6  | 7  | 5  |
| *Enhertu* | 1976  | 5  | 37  | 38  | 714  | 5  | 40  | 39  |
| *Zoladex* | 884  | 2  | 5  | 6  | 296  | 2  | 7  | 6  |
| *Truqap* | 495  | 1  | 85  | 85  | 193  | 1  | 55  | 54  |
| *Imjudo* | 253  | 1  | 22  | 21  | 84  | 1  | 16  | 14  |
| *Datroway* | 38  | -  | n/m  | n/m  | 24  | -  | n/m  | n/m  |
| Other Oncology | 323  | 1  | (10) | (9) | 107  | 1  | (9) | (10) |
| **Oncology Product Revenue** | **18590**  | **43**  | **16**  | **16**  | **6636**  | **44**  | **19**  | **18**  |
| *Farxiga* | 6345  | 15  | 11  | 11  | 2135  | 14  | 10  | 8  |
| *Crestor* | 942  | 2  | 5  | 6  | 306  | 2  | 1  | (1) |
| *Brilinta* | 665  | 2  | (33) | (33) | 146  | 1  | (55) | (56) |
| *Lokelma* | 517  | 1  | 32  | 31  | 189  | 1  | 32  | 30  |
| *Seloken* | 469  | 1  | 1  | 3  | 160  | 1  | 6  | 6  |
| roxadustat | 229  | 1  | (12) | (12) | 77  | 1  | (18) | (19) |
| *Wainua* | 143  | -  | >3x  | >3x  | 59  | -  | >2x  | >2x  |
| Other CVRM | 418  | 1  | (24) | (24) | 144  | 1  | (18) | (19) |
| **CVRM Product Revenue** | **9728**  | **23**  | **4**  | **5**  | **3216**  | **21**  | **2**  | **-**  |
| *Symbicort* | 2180  | 5  | (1) | -  | 742  | 5  | 5  | 4  |
| *Fasenra* | 1451  | 3  | 19  | 19  | 530  | 3  | 22  | 20  |
| *Breztri* | 906  | 2  | 26  | 26  | 323  | 2  | 21  | 20  |
| *Tezspire* | 770  | 2  | 64  | 63  | 287  | 2  | 50  | 47  |
| *Pulmicort* | 357  | 1  | (31) | (30) | 93  | 1  | (33) | (35) |
| *Saphnelo* | 483  | 1  | 48  | 47  | 180  | 1  | 45  | 44  |
| *Airsupra* | 115  | -  | >2x  | >2x  | 45  | -  | >2x  | >2x  |
| Other R&I | 231  | 1  | (11) | (11) | 59  | -  | (24) | (24) |
| **R&I Product Revenue** | **6493**  | **15**  | **13**  | **13**  | **2259**  | **15**  | **15**  | **14**  |
| *Beyfortus* | 474  | 1  | 80  | 78  | 236  | 2  | 29  | 29  |
| *Synagis* | 220  | 1  | (36) | (35) | 58  | -  | (37) | (40) |
| *FluMist* | 132  | -  | 21  | 19  | 122  | 1  | 21  | 20  |
| Other V&I | -  | -  | n/m  | n/m  | -  | -  | n/m  | n/m  |
| **V&I Product Revenue** | **826**  | **2**  | **9**  | **9**  | **416**  | **3**  | **3**  | **2**  |
| *Ultomiris* | 3453  | 8  | 22  | 21  | 1225  | 8  | 19  | 17  |
| *Soliris* | 1436  | 3  | (30) | (28) | 462  | 3  | (24) | (24) |
| *Strensiq* | 1188  | 3  | 19  | 19  | 441  | 3  | 29  | 28  |
| *Koselugo* | 498  | 1  | 36  | 34  | 224  | 1  | 88  | 79  |
| Other Rare Disease | 177  | -  | 18  | 18  | 64  | -  | 31  | 26  |
| **Rare Disease Product Revenue** | **6752**  | **16**  | **6**  | **6**  | **2416**  | **16**  | **12**  | **11**  |
| *Nexium* | 638  | 1  | (7) | (5) | 204  | 1  | (6) | (5) |
| Others | 116  | -  | (27) | (26) | 33  | -  | (39) | (39) |
| **Other Medicines Product Revenue** | **754**  | **2**  | **(11)** | **(9)** | **237**  | **2**  | **(12)** | **(12)** |
| **Product Revenue** | **43143**  | **100**  | **10**  | **11**  | **15180**  | **100**  | **12**  | **11**  |
|  ***Alliance Revenue included above:*** |  |  |  |  |  |  |  |  |
| *Enhertu* | 1291  | 3  | 24  | 24  | 457  | 3  | 26  | 24  |
| *Tezspire* | 453  | 1  | 50  | 50  | 168  | 1  | 37  | 37  |
| *Beyfortus* | 252  | 1  | >3x  | >3x  | 142  | 1  | >2x  | >2x  |
| *Datroway* | 38  | -  | n/m  | n/m  | 24  | -  | n/m  | n/m  |
| Other Alliance Revenue | 74  | -  | (2) | (2) | 24  | -  | (8) | (8) |
| **Alliance Revenue** | **2108**  | **5**  | **41**  | **41**  | **815**  | **5**  | **46**  | **44**  |

---

Table 4: Collaboration Revenue

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **9M 2025**  | **% Change** | **% Change** | **Q3 2025**  | **% Change** | **% Change** |
|  | **$m**  | **Actual**  | **CER**  | **$m**  | **Actual**  | **CER**  |
| *Farxiga:* sales milestones | 81 | 56  | 56  | 5  | 51  | 43  |
| Others | 12 | (79) | (80) | 6  | (90) | (90) |
| **Collaboration Revenue** | **93** | **(14)** | **(15)** | **11**  | **(81)** | **(82)** |

---

Table 5: Total Revenue by Therapy Area

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | **% Change** | **% Change** | | | **% Change** | **% Change** |
|  | **9M 2025** <br>**$m**  | <br>**% Total** | **Actual**  | **CER**  | **Q3 2025** <br>**$m**  | <br>**% Total** | **Actual**  | **CER**  |
| Oncology | 18591  | 43  | 16  | 16  | 6636  | 44  | 19  | 18  |
| *CVRM* | *9809*  | *23*  | *5*  | *5*  | *3221*  | *21*  | *2*  | *-*  |
| *R&I* | *6493*  | *15*  | *13*  | *13*  | *2259*  | *15*  | *15*  | *14*  |
| *V&I* | *826*  | *2*  | *2*  | *2*  | *416*  | *3*  | *(10)* | *(11)* |
| BioPharmaceuticals | 17129  | 40  | 7  | 8  | 5896  | 39  | 6  | 4  |
| Rare Disease | 6752  | 16  | 6  | 6  | 2416  | 16  | 12  | 11  |
| Other Medicines | 764  | 2  | (9) | (8) | 242  | 2  | (10) | (10) |
| **Total Revenue** | **43236**  | **100**  | **10**  | **11**  | **15191**  | **100**  | **12**  | **10**  |

---

Table 6: Total Revenue by region

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | **% Change** | **% Change** | | | **% Change** | **% Change** |
|  | **9M 2025** <br>**$m**  | <br>**% Total** | **Actual**  | **CER**  | **Q3 2025** <br>**$m**  | <br>**% Total** | **Actual**  | **CER**  |
| US | 18517  | 43  | 11  | 11  | 6548  | 43  | 9  | 9  |
| *Emerging Markets ex. China* | *6378*  | *15*  | *16*  | *21*  | *2196*  | *14*  | *25*  | *25*  |
| *China* | *5279*  | *12*  | *5*  | *5*  | *1764*  | *12*  | *6*  | *5*  |
| Emerging Markets | 11657  | 27  | 11  | 13  | 3960  | 26  | 16  | 15  |
| Europe | 9160  | 21  | 11  | 9  | 3334  | 22  | 16  | 10  |
| Established ROW | 3902  | 9  | 6  | 5  | 1349  | 9  | 7  | 5  |
| **Total Revenue** | **43236**  | **100**  | **10**  | **11**  | **15191**  | **100**  | **12**  | **10**  |

---

 <u>Total Revenue by Medicine</u>

Oncology

 *Tagrisso*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Strong demand growth across all indications and key regions, leading combination in 1L NSCLC (FLAURA2) |
| US | 2222  | 11  | 11  | ∗Underlying demand growth more than offset Medicare Part D redesign |
| Emerging Markets | 1509  | 11  | 13  | ∗Favourable tender order timings in Q3 2025 |
| Europe | 1030  | 8  | 5  | ∗Demand growth partially offset by pricing pressure in certain major markets |
| Established RoW | 591  | 5  | 5  |  |
| **Total** | **5352**  | **10**  | **10**  |  |

---

 *Imfinzi*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025**<br> **$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Strong growth from new launch indications in bladder cancer (NIAGARA) and lung cancer (ADRIATIC, AEGEAN) |
| US | 2484  | 32  | 32  | ∗Demand growth across all indications, particularly new launches |
| Emerging Markets | 463  | 27  | 33  | ∗Increased demand in GI (HIMALAYA, TOPAZ-1) and new launches in lung cancer |
| Europe | 879  | 26  | 24  | ∗Growth from GI indications and continued momentum from lung cancer launches |
| Established RoW | 491  | (6) | (7) | ∗Mandatory price reductions in Japan in Feb 2024 (25%), and Aug 2024 (11%), increased competition in BTC (TOPAZ-1) |
| **Total** | **4317**  | **25**  | **25**  |  |

---

 *Calquence*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Growth from sustained BTKi leadership in front-line CLL (ELEVATE-TN) |
| US | 1702  | 5  | 5  | ∗Growth in new starts in CLL, 1L MCL (ECHO) launch and improved affordability offsetting Medicare Part D redesign and formulary discounts to secure preferential formulary placement |
| Emerging Markets | 164  | 41  | 48  |  |
| Europe | 569  | 16  | 14  | ∗Early launch momentum in fixed duration 1L CLL (AMPLIFY) |
| Established RoW | 116  | 18  | 20  |  |
| **Total** | **2551**  | **10**  | **10**  |  |

---

 *Lynparza*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Sustained global PARP inhibitor market leadership across four tumour types (ovarian, breast, prostate, pancreatic) |
| US | 1054  | 10  | 10  | ∗Share gains across ovarian, breast and prostate indications |
| Emerging Markets | 487  | 2  | 4  | ∗Affected by generic launches in China in Q4 2024 |
| Europe | 667  | 9  | 7  | ∗Launches in breast and prostate cancers (OlympiA and PROpel) |
| Established RoW | 193  | 3  | 3  | ∗Gains in 1L ovarian cancer, increasing share of pMMR endometrial cancer |
| **Total** | **2401**  | **8**  | **7**  |  |

---

 *Enhertu*

Combined sales of *Enhertu*, recorded by Daiichi Sankyo and AstraZeneca, amounted to $3,575m in 9M 2025 (9M 2024: $2,729m). US in-market sales, recorded by Daiichi Sankyo, amounted to $1,734m in 9M 2025 (9M 2024: $1,342m). AstraZeneca's European revenue includes a mid-single-digit percentage royalty on Daiichi Sankyo's sales in Japan, recorded as Alliance Revenue.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Standard of care in HER2-positive (DESTINY-Breast03) and HER2-low (DESTINY-Breast04) metastatic breast cancer, early uptake in other cancers<br> ∗ |
| US | 834  | 30  | 30  | ∗Accelerated uptake in chemotherapy naïve HER2-low and - ultralow breast cancer (DESTINY-Breast06) |
| Emerging Markets | 590  | 67  | 75  | ∗Rapid adoption post-NRDL enlistment of HER2-positive and HER2-low breast cancer from 1 January 2025 |
| Europe | 489  | 22  | 20  | ∗Early launch uptake in chemotherapy naïve HER2-low breast cancer |
| Established RoW | 63  | 34  | 38  |  |
| **Total** | **1976**  | **37**  | **38**  |  |

---

Other Oncology medicines

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  |  |
| *Zoladex* | 884  | 5  | 6  | ∗Growth across Emerging Markets |
| *Truqap* | 495  | 85  | 85  | ∗Demand growth in second-line biomarker-altered metastatic breast cancer |
| *Imjudo* | 253  | 22  | 21  | ∗Continued growth driven by lung (POSEIDON) and HCC (HIMALAYA) |
| *Datroway* | 38  | n/m | n/m | ∗Continued uptake in breast cancer; initial use in lung cancer following US launch |
| Other Oncology | 323  | (10) | (9) | ∗*Faslodex* generic erosion across markets |

---

 *Other Oncology includes $23m of Total Revenue from Orpathys, partnered with HUTCHMED.*

BioPharmaceuticals - CVRM

 *Farxiga*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Growth driven by HF and CKD indications, SGLT2 class growth supported by cardiorenal guidelines |
| US | 1244  | (3) | (3) | ∗Prior year period benefitted from launch of authorised generic |
| Emerging Markets | 2623  | 18  | 21  | ∗Continued strong growth despite generic competition in some markets |
| Europe | 2147  | 13  | 10  | ∗Demand growth, impact from generic entry in the UK in Q3 2025 |
| Established RoW | 413  | 11  | 11  |  |
| **Total** | **6426**  | **11**  | **12**  |  |

---

Other CVRM medicines

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  |  |
| *Crestor* | 942  | 5  | 6  | ∗Continued sales growth driven by Emerging Markets |
| *Brilinta* | 665  | (33) | (33) | ∗Decline driven by generic entry in the US and Europe in Q2 2025 |
| *Seloken* | 469  | 1  | 3  | ∗Vast majority of revenue growth driven by Emerging Markets |
| *Lokelma* | 517  | 32  | 31  | ∗Strong growth in all major regions with continued launches in new markets |
| roxadustat | 229  | (12) | (12) | ∗Decline driven by generic competition |
| *Wainua* | 143  | >3x | >3x | ∗Majority of revenue from US, first launches in ex-US markets in Q2 2025 |
| Other CVRM | 418  | (24) | (24) |  |

---

BioPharmaceuticals - R&I

 *Symbicort*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Sustained market leader in a stable ICS/LABA class, treating COPD and asthma |
| US | 903  | 2  | 2  | ∗Demand for authorised generic partially offsetting brand price pressures |
| Emerging Markets | 624  | (4) | (3) | ∗China affected by ICS/LABA class erosion in COPD in favour of FDC triple therapy |
| Europe | 406  | (2) | (4) | ∗Continued generic erosion |
| Established RoW | 247  | 3  | 5  |  |
| **Total** | **2180**  | **(1)** | **-**  |  |

---

 *Fasenra*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Expanded severe eosinophilic asthma market share leadership in IL-5 class, further fuelled by first wave market launches for EGPA indication |
| US | 886  | 18  | 18  | ∗Sustained double-digit volume growth with expanded class leadership |
| Emerging Markets | 81  | 18  | 22  | ∗Asthma launch momentum across key markets  |
| Europe | 351  | 19  | 17  | ∗Sustained leadership in severe eosinophilic asthma |
| Established RoW | 133  | 26  | 27  | ∗Strong growth supported by recent EGPA launch in Japan |
| **Total** | **1451**  | **19**  | **19**  |  |

---

 *Breztri*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Fastest growing medicine within the expanding FDC triple class (ICS/LABA/LAMA), treating COPD |
| US | 462  | 26  | 26  | ∗Consistent share growth within expanding FDC triple class |
| Emerging Markets | 239  | 20  | 21  | ∗Market share leadership in China with strong FDC triple class penetration |
| Europe | 136  | 34  | 31  | ∗Sustained growth from market share gain and new launches |
| Established RoW | 69  | 31  | 31  | ∗Increasing market share in Japan |
| **Total** | **906**  | **26**  | **26**  |  |

---

 *Tezspire*

Combined sales of *Tezspire*, recorded by Amgen and AstraZeneca, amounted to $1,321m in 9M 2025 (9M 2024: $843m).

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Sustained demand growth in severe asthma with launch momentum across multiple markets |
| US | 453  | 50  | 50  | ∗Continued strong demand growth with increasing new patient share volumes in biologics segment |
| Emerging Markets | 24  | >3x  | >3x  | ∗Strong continued launch uptake |
| Europe | 207  | 98  | 93  | ∗Maintained new-to-brand leadership across multiple markets and new launches |
| Established RoW | 86  | 55  | 55  | ∗Strong growth driven by Japan |
| **Total** | **770**  | **64**  | **63**  |  |

---

Other R&I medicines

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  |  |
| *Pulmicort* | 357  | (31) | (30) | ∗Generic competition in Emerging Markets (~80% of revenue) |
| *Saphnelo* | 483  | 48  | 47  | ∗Strong US demand growth, ongoing launches in Europe and Established RoW |
| *Airsupra* | 115  | >2x | >2x | ∗Strong US launch momentum and volume uptake |
| Other R&I | 231  | (11) | (11) |  |

---

BioPharmaceuticals - V&I

 *Beyfortus* Total Revenue reflects the sum of Product Sales from AstraZeneca's sales of manufactured *Beyfortus* product to Sanofi and Alliance Revenue from AstraZeneca's share of gross profits and royalties on sales of *Beyfortus* in major markets outside the US.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  |  |
| *Beyfortus* | 474  | 49  | 47  | ∗Increased capacity and strong demand |
| *Synagis* | 220  | (36) | (35) | ∗Competition from *Beyfortus* |
| *FluMist* | 132  | 21  | 19  |  |
| Other V&I | 0  | n/m | n/m |  |

---

Rare Disease

 *Ultomiris*

 *Ultomiris* Total Revenue includes sales of *Voydeya*, which is approved as an add on treatment to *Ultomiris* and *Soliris* for the ~20-30% of PNH patients who experience clinically significant EVH.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Growth due to patient demand, both naïve to branded medicines and conversion from *Soliris* in all indications (gMG, NMOSD, aHUS and PNH) |
| US | 1961  | 20  | 20  | ∗Demand growth across indications, including within the competitive gMG and PNH landscapes, minimal impact from Medicare Part D redesign |
| Emerging Markets | 177  | 92  | >2x  | ∗Expansion into new markets and growth in patient demand |
| Europe | 769  | 18  | 16  | ∗Strong demand growth following recent launches; competition in gMG and PNH |
| Established RoW | 546  | 17  | 16  | ∗Continued conversion and strong demand following new launches |
| **Total** | **3453**  | **22**  | **21**  |  |

---

 *Soliris*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Decline driven by conversion of patients to *Ultomiris* in all indications (gMG, NMOSD, aHUS, PNH)*,* competition, and biosimilar pressure in Europe |
| US | 844  | (28) | (28) | ∗Competition in gMG and PNH, biosimilars launched in April 2025 |
| Emerging Markets | 327  | (11) | (2) | ∗ |
| Europe | 159  | (54) | (55) | ∗Biosimilar competition in PNH and aHUS |
| Established RoW | 106  | (35) | (34) | &nbsp;&nbsp;&nbsp;&nbsp; ● Driven by conversion to *Ultomiris* |
| **Total** | **1436**  | **(30)** | **(28)** |  |

---

 *Strensiq*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  | ∗Growth driven by continued patient demand and geographic expansion |
| US | 953  | 17  | 17  | ∗Demand growth, offset by Medicare Part D redesign |
| Emerging Markets | 61  | 58  | 61  |  |
| Europe | 89  | 22  | 19  |  |
| Established RoW | 85  | 23  | 21  |  |
| **Total** | **1188**  | **19**  | **19**  |  |

---

Other Rare Disease medicines

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  |  |
| *Koselugo* | 498 | 36 | 34 | ∗Growth driven by continued patient demand and geographic expansion. Q3 2025 benefitted from favourable timing of tender orders in Emerging Markets |
| Other Rare Disease | 177 | 18 | 18 | ∗Other Rare Disease medicines include *Kanuma* and *Beyonttra* (JP only) |

---

Other Medicines

---

| | | | | |
|:---|:---|:---|:---|:---|
| **9M 2025$m** | **Total** <br> **Revenue**  | **% Change** <br> **Actual CER**  | **% Change** <br> **Actual CER**  |  |
| *Nexium* | 638 | (7) | (5) | ∗Growth in Emerging Markets, generic erosion elsewhere |
| Others | 126 | (20) | (20) | ∗Generic erosion |

---

&nbsp;&nbsp; R&D progress<br>

This section covers R&D events and milestones that occurred between 29 July 2025 and 5 November 2025. A comprehensive view of AstraZeneca's pipeline of medicines in human trials can be found in the latest Clinical Trials Appendix, available on AstraZeneca's <u>investor relations webpage</u>. The Clinical Trials Appendix includes tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the pipeline.

Oncology

AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical congresses since the prior results announcement: the IASLC 2025 World Conference on Lung Cancer (WCLC) and the European Society of Medical Oncology Congress 2025 (ESMO). Across the two meetings, more than 160 abstracts were presented featuring 20 approved and potential new medicines including 35 oral presentations.

 *Calquence*

---

| | | |
|:---|:---|:---|
| **Approval**<br> JP | **ECHO**<br> August 2025<br> *New disclosure* | ∗For mantle cell lymphoma in previously untreated diseases: in combination with bendamustine hydrochloride and rituximab (genetical recombination). |
| **Approval**<br> JP | **ACE-LY-004**<br> August 2025<br> *New disclosure* | ∗For mantle cell lymphoma in relapsed or refractory diseases. |

---

 *Datroway*

---

| | | |
|:---|:---|:---|
| **Approval**<br> CN | **TROPION-Breast01**<br> August 2025<br> *New disclosure* | ∗For the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine therapy and at least one line of chemotherapy in the advanced setting. |
| **Data presentation**<br> ESMO | **TROPION-Breast02**<br> October 2025 | ∗Positive results from the TROPION-Breast02 Phase III trial showed *Datroway* demonstrated a 5.0-month improvement in median OS (HR 0.79; 95% CI 0.64-0.98; p=0.0291) and reduced the risk of disease progression or death by 43% (HR 0.57; 95% CI 0.47-0.69; p<0.0001) compared to chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. |

---

 *Enhertu*

---

| | | |
|:---|:---|:---|
| **Approval**<br> JP | **DESTINY-Breast06**<br> August 2025 | ∗For the treatment of adult patients with HR-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) unresectable or recurrent breast cancer. |
| **Priority Review**<br> US | **DESTINY-Breast09**<br> September 2025 | ∗In combination with pertuzumab for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. |
| **Data presentation**<br> ESMO | **DESTINY-Breast11**<br> October 2025 | ∗Positive results from the DESTINY-Breast11 Phase III trial showed *Enhertu* followed by THP resulted in a pCR rate of 67.3% compared with 56.3% for ddAC-THP, representing a pCR rate improvement of 11.2%, in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. |
| **Data presentation**ESMO | **DESTINY-Breast05**<br> October 2025 | ∗Positive results from the DESTINY-Breast05 Phase III trial showed *Enhertu* significantly reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 as a post-neoadjuvant treatment (HR 0.47, 95% CI 0.34-0.66, p<0.0001) in patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment. At three years, 92.4% of patients in the *Enhertu* arm were alive and free of invasive disease, compared with 83.7% of those in the T-DM1 arm. |

---

 *Imfinzi*

---

| | | |
|:---|:---|:---|
| **Approval**<br> JP | **NIAGARA**<br> September 2025<br> *New disclosure* | ∗Neoadjuvant and adjuvant therapy in bladder cancer. |
| **Approval**<br> JP | **AEGEAN**<br> September 2025<br> *New disclosure* | ∗Neoadjuvant and adjuvant treatment in non-small cell lung cancer. |
| **Data presentation**<br> ESMO | **MATTERHORN**<br> October 2025 | ∗Positive results from the final OS analysis of the MATTERHORN Phase III trial showed perioperative treatment with *Imfinzi* in combination with standard-of-care FLOT chemotherapy reduced the risk of death by 22% compared with chemotherapy alone (HR 0.78; 95% CI 0.63-0.96; p=0.021) in patients with resectable, early-stage and locally advanced and GEJ cancers. |
| **Data presentation**<br> ESMO | **POTOMAC**<br> October 2025 | ∗Positive results from the POTOMAC Phase III trial showed adding one year of treatment with *Imfinzi* to BCG induction and maintenance therapy demonstrated a 32% reduction in the risk of high-risk disease recurrence or death versus the comparator arm (HR 0.68; 95% CI 0.50-0.93; p=0.0154) in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer. |

---

 *Lynparza*

---

| | | |
|:---|:---|:---|
| **Approval**<br> CN | **PROpel**<br> July 2025<br> *New disclosure* | ∗In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with g/sBRCAm mCRPC. |

---

 *Tagrisso*

---

| | | |
|:---|:---|:---|
| **Data presentation**<br> WCLC<br>| **FLAURA2**<br> September 2025 | ∗Positive results from the final OS analysis of the FLAURA2 Phase III trial showed Tagrisso with the addition of pemetrexed and platinum-based chemotherapy demonstrated a median OS of nearly four years (47.5 months) compared to approximately three years (37.6 months) for *Tagrisso* monotherapy in the 1st-line treatment of patients with locally advanced or metastatic *EGFR*m NSCLC. |

---

BioPharmaceuticals - CVRM

AstraZeneca presented 32 abstracts and 13 posters alongside two hot-line oral presentations at the European Society of Cardiology (ESC) in Madrid, Spain.

baxdrostat

---

| | | |
|:---|:---|:---|
| **Data presentation**<br> ESC | **BaxHTN**<br> August 2025 | ∗Positive results from the BaxHTN Phase III trial showed that baxdrostat met the primary and all secondary endpoints, delivering meaningful and sustained blood pressure reductions in patients with hard-to-control hypertension. At week 12, the absolute reduction from baseline in mean seated SBP was 15.7 mmHg (95% CI, -17.6 to -13.7) and placebo-adjusted reduction was 9.8 mmHg (95% CI, -12.6 to -7.0; p<0.001) for the 2mg dose. Results were consistent across both uncontrolled and treatment-resistant subgroups. |
| **Phase III readout** | **Bax24**<br> October 2025 | ∗Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events. |

---

BioPharmaceuticals - R&I

 *Airsupra*

---

| | | |
|:---|:---|:---|
| **Approval**<br> US<br>| **BATURA**<br> October 2025<br>| ∗US Prescribing Information now includes clinically meaningful evidence in reducing severe exacerbations from the BATURA study in patients with mild asthma.  |

---

 *Fasenra*

---

| | | |
|:---|:---|:---|
| **Phase III readout**<br>| **RESOLUTE**<br> September 2025<br>| ∗ The RESOLUTE Phase III trial despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic obstructive pulmonary disease. |

---

 *Saphnelo*

---

| | | |
|:---|:---|:---|
| **Phase III readout**<br>| **TULIP-SC**<br> September 2025<br>| ∗Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus showed that the subcutaneous administration of *Saphnelo* demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo. The TULIP-SC interim results were presented at the American College of Rheumatology annual meeting in October 2025. |
| **CHMP opinion**<br> EU | **TULIP-SC**<br> October 2025 | ∗Recommended for approval as a self-administered once-weekly pre-filled pen for adult patients with systemic lupus erythematosus on top of standard therapy. |

---

 *Tezspire*

---

| | | |
|:---|:---|:---|
| **Approval**<br> EU | **WAYPOINT**<br> October 2025 | ∗As an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP who have not adequately responded to standard therapy (systemic corticosteroids and/or surgery). |
| **Approval**<br> US | **WAYPOINT**<br> October 2025 | ∗As an add-on maintenance treatment of adult and paediatric patients aged 12 years and older with inadequately controlled CRSwNP. |

---

Rare Disease

Alexion, AstraZeneca Rare Disease, delivered 18 presentations, including four oral presentations, from its leading rare neurology portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco, California.

 *Koselugo*

---

| | | |
|:---|:---|:---|
| **Approval**<br> Japan<br>| **KOMET**<br> August 2025 | ∗For the treatment of adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1. |
| **Approval**<br> EU | **KOMET**<br> October 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ∗For the treatment of adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1.<br>|
| **Approval**<br> Japan | **SPRINKLE**<br> September 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ∗Granule formulation for paediatric patients one year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.<br>|
| **Approval**<br> US | **SPRINKLE**<br> September 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ∗Granule formulation for paediatric patients one year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.<br>|

---

 *Ultomiris*

---

| | | |
|:---|:---|:---|
| **Approval**<br> China<br>| **CHAMPION-NMOSD**<br> August 2025<br>| ∗For the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive. |

---

gefurulimab

---

| | | |
|:---|:---|:---|
| **Data presentation**<br> AANEM/MGFA | **PREVAIL**<br> October 2025 | ∗Positive results from the PREVAIL Phase III trial demonstrated an improvement from baseline in MG-ADL total score at week 26 compared to placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001). A clinically meaningful improvement was observed as early as week one, and was sustained through week 26. Additionally, a clinically meaningful improvement in key secondary endpoint, QMG total score, was seen as early as week four (treatment difference: -1.8 [ 95% CI: -2.5, -1.1], p<0.0001) and was sustained through week 26 (treatment difference: -2.1 [95% CI: -3.1, -1.1], p<0.0001). |

---

Sustainability

Sustainability highlights

For the third consecutive year, TIME Magazine recognised AstraZeneca as one of the World's Best Companies with the Company ranking at 43 out of 1,000 global companies and as the top pharmaceutical company in terms of sustainability transparency. AstraZeneca also secured fifth place in Sustainability Magazine's Top 250 World's Most Sustainable Companies 2025, affirming its status as a global leader in responsible business and pharmaceutical innovation.

AstraZeneca engaged on climate action, health systems resilience and health equity at the United Nations (UN) General Assembly High-Level Meeting on non-communicable diseases (NCDs) and Climate Week NYC in September through over 100 engagements. EVP Global Operations, IT and Chief Sustainability Officer Pam Cheng represented the private sector at the UN alongside governments, NGOs and academia, focusing on the need to tackle NCDs.

Chair Michel Demaré also joined a group of 25 global health leaders, including former heads of state and ministers, calling for action on this topic through an Open Letter in POLITICO, with a focus on the human, social and financial impacts of chronic disease and targeted solutions.

Sustainability impact

Climate and nature

- The Company focused on sustainable respiratory care at the European Respiratory Society (ERS), hosting a sustainability symposium, key engagements and running a sustainable booth with a living lung installation.

- The Company won a 2025 Freezer Challenge Award for the fourth time from My Green Lab and the International Institute for Sustainable Laboratories, recognised as the Top Organization in the biotech and pharmaceutical sector for energy savings and best-in-class cold storage management.

Health equity

- At EXPO 2025, the Company advanced priorities to transform lung health in Japan and Asia-Pacific through best practice sharing on screening and integrated disease management. The Company convened national and international government and clinical experts in lung cancer and COPD to further collaboration for high-risk patients and reduce mortality in Japan.

- AstraZeneca's Young Health Programme (YHP) received the ACE Award for Workforce Innovation and Global Impact at the Healthcare Businesswomen's Association's (HBA) annual conference, recognising how the programme supports employee engagement, advances health equity and strengthens health systems through youth empowerment. YHP was also recognised with the Third Sector Award for Large Corporate Partnership of the Year with Plan International UK.

- The Company expanded its Healthy Heart Africa (HHA) programme in the Côte d'Ivoire, in partnership with the Ministry of Health, to include chronic kidney disease (CKD) care in addition to hypertension. The programme also expanded in Rwanda, where it will develop a protocol for CKD care in primary health, with training to be cascaded to healthcare providers, in collaboration with PATH.

Health systems resilience

- The Partnership for Health System Sustainability and Resilience (PHSSR) published its summary report on Acting Early on NCDs which captures highlights from research conducted in eight countries on health systems' capability to act early on cancers, chronic respiratory diseases and CVRM. AstraZeneca engaged on its findings with the World Economic Forum Sustainable Development Impact Meetings in New York.

Operating and financial review

Reporting currency

All narrative on growth and results in this section is based on actual exchange rates, and financial figures are in US$ millions ($m), unless stated otherwise.

Reporting period

The performance shown in this announcement covers the nine-month period to 30 September 2025 ('the period' or '9M 2025') compared to the nine-month period to 30 September 2024 ('9M 2024'), or the three-month period to 30 September 2025 ('the quarter' or 'Q3 2025') compared to the three-month period to 30 September 2024 ('Q3 2024'), unless stated otherwise.

Core financial measures

Core financial measures, EBITDA, Net debt, Gross Margin, Operating Margin and CER are non-GAAP financial measures because they cannot be derived directly from the Group's Condensed consolidated interim financial statements.

Management believes that these non-GAAP financial measures, when provided in combination with Reported results, provide investors and analysts with helpful supplementary information to understand better the financial performance and position of the Group on a comparable basis from period to period.

These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP.

Core financial measures (cont.)

Core financial measures are adjusted to exclude certain significant items:

- Charges and provisions related to our global restructuring programmes, which includes charges that relate to the impact of restructuring programmes on our capitalised manufacturing assets and IT assets

- Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges relating to IT assets

- Other specified items, principally comprising acquisition-related costs and credits, which include the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain Other payables arising from intangible asset acquisitions, remeasurement adjustments relating to certain Other payables and debt items assumed from the Alexion acquisition and legal settlements

- The tax effects of the adjustments above are excluded from the Core Tax charge

Details on the nature of Core financial measures are provided on page 70 of the <u>Annual Report and Form 20-F Information 2024</u>.

Reference should be made to the Reconciliation of Reported to Core financial measures table included in the Financial Performance section in this announcement.

Definitions

Gross Margin is defined as Gross Profit as a percentage of Total Revenue.

EBITDA is defined as Reported Profit before tax after adding back Net finance expense, results from Joint ventures and associates and charges for Depreciation, amortisation and impairment. Reference should be made to the Reconciliation of Reported Profit before tax to EBITDA included in the Financial Performance section in this announcement.

Operating margin is defined as Operating profit as a percentage of Total Revenue.

Net debt is defined as Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash equivalents, Other investments, and Net derivative financial instruments. Reference should be made to Note 3 'Net debt', included in the Notes to the interim financial statements in this announcement.

The Company strongly encourages investors and analysts not to rely on any single financial measure, but to review AstraZeneca's financial statements, including the Notes thereto, and other available Company reports, carefully and in their entirety.

Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree to totals.

Financial performance

Table 7: Reported Profit and Loss

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | **% Change** | **% Change** | | | **% Change** | **% Change** |
|  | **9M 2025** <br>**$m**  | **9M 2024**<br>**$m**  | **Actual**  | **CER**  | **Q3 2025** <br>**$m**  | **Q3 2024**<br>**$m**  | **Actual**  | **CER**  |
| *- Product Sales* | *41035*  | *37576*  | *9*  | *9*  | *14365*  | *12947*  | *11*  | *9*  |
| *- Alliance Revenue* | *2108*  | *1498*  | *41*  | *41*  | *815*  | *559*  | *46*  | *44*  |
| Product Revenue | 43143  | 39074  | 10  | 11  | 15180  | 13506  | 12  | 11  |
| Collaboration Revenue | 93  | 108  | (14) | (15) | 11  | 59  | (81) | (82) |
| **Total Revenue** | **43236**  | **39182**  | **10**  | **11**  | **15191**  | **13565**  | **12**  | **10**  |
| Cost of sales | (7515) | (7482) | -  | 2  | (2801) | (3081) | (9) | (10) |
| **Gross profit** | **35721**  | **31700**  | **13**  | **13**  | **12390**  | **10484**  | **18**  | **16**  |
| Distribution expense | (426) | (412) | 3  | 4  | (148) | (145) | 2  | -  |
| R&D expense | (10370) | (8906) | 16  | 16  | (3663) | (3115) | 18  | 16  |
| SG&A expense | (14441) | (14567) | (1) | (1) | (5085) | (5143) | (1) | (3) |
| Other operating income & expense | 281  | 152  | 85  | 87  | 89  | 25  | >3x | >3x |
| **Operating profit** | **10765**  | **7967**  | **35**  | **35**  | **3583**  | **2106**  | **70**  | **64**  |
| Net finance expense | (985) | (919) | 7  | 7  | (349) | (274) | 27  | 25  |
| Joint ventures and associates | (7) | (23) | (68) | (70) | 10  | (4) | n/m | n/m |
| **Profit before tax** | **9773**  | **7025**  | **39**  | **38**  | **3244**  | **1828**  | **77**  | **70**  |
| Taxation | (1869) | (1484) | 26  | 25  | (709) | (395) | 79  | 72  |
| *Tax rate* | *19%*  | *21%*  |  |  | *22%*  | *22%*  |  |  |
| **Profit after tax** | **7904**  | **5541**  | **43**  | **42**  | **2535**  | **1433**  | **77**  | **70**  |
| **Earnings per share** | **$5.10**  | **$3.57**  | **43**  | **42**  | **$1.64**  | **$0.92**  | **77**  | **70**  |

---

Table 8: Reconciliation of Reported Profit before tax to EBITDA

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | **% Change** | **% Change** | | | **% Change** | **% Change** |
|  | **9M 2025** <br>**$m**  | **9M 2024**<br>**$m**  | **Actual**  | **CER**  | **Q3 2025** <br>**$m**  | **Q3 2024**<br>**$m**  | **Actual**  | **CER**  |
| **Reported Profit before tax** | **9773**  | **7025**  | **39**  | **38**  | **3244**  | **1828**  | **77**  | **70**  |
| Net finance expense | 985  | 919  | 7  | 7  | 349  | 274  | 27  | 25  |
| Joint ventures and associates | 7  | 23  | (68) | (70) | (10) | 4  | n/m | n/m |
| Depreciation, amortisation and impairment | 4222  | 4351  | (3) | (4) | 1549  | 1817  | (15) | (16) |
| **EBITDA** | **14987**  | **12318**  | **22**  | **21**  | **5132**  | **3923**  | **31**  | **28**  |

---

Table 9: Reconciliation of Reported to Core financial measures: 9M 2025

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | | | **% Change** | **% Change** |
| For the **nine months** ended 30 September<br>| **Reported**<br>**$m**  | **Restructuring**<br>**$m**  | **Intangible Asset Amortisation & Impairments**<br>**$m**  | **Other**<br>**$m**  | **Core**<br>**$m**  | **Actual**  | **CER**  |
| **Gross profit** | **35721**  | **(61)** | **24**  | **12**  | **35696**  | **10**  | **10**  |
| *- Gross Margin* | *83%*  |  |  |  | *83%*  | *-*  | *-*  |
| Distribution expense | (426) | -  | -  | -  | (426) | 3  | 4  |
| R&D expense | (10370) | 134  | 141  | 4  | (10091) | 17  | 16  |
| *- R&D % of Total Revenue* | *24%*  |  |  |  | *23%*  | *-1pp*  | *-1pp*  |
| SG&A expense | (14441) | 113  | 3038  | 209  | (11081) | 3  | 3  |
| *- SG&A % of Total Revenue* | *33%*  |  |  |  | *26%*  | *+2pp*  | *+2pp*  |
| Total operating expense | (25237) | 247  | 3179  | 213  | (21598) | 9  | 9  |
| Other operating income & expense | 281  | (6) | -  | 7  | 282  | 88  | 91  |
| **Operating profit** | **10765**  | **180**  | **3203**  | **232**  | **14380**  | **13**  | **13**  |
| *- Operating Margin* | *25%*  |  |  |  | *33%*  | *+1pp*  | *+1pp*  |
| Net finance expense | (985) | -  | -  | 162  | (823) | (4) | (4) |
| Taxation | (1869) | (49) | (611) | (98) | (2627) | 11  | 11  |
| **EPS** | **$5.10**  | **$0.08**  | **$1.68**  | **$0.18**  | **$7.04**  | **15**  | **15**  |

---

Table 10: Reconciliation of Reported to Core financial measures: Q3 2025

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| For the **quarter** ended 30 September<br>| **Reported** | **Restructuring** | **Intangible Asset Amortisation & Impairments** | **Other** | **Core** | **% Change** | **% Change** |
|  | **$m**  | **$m**  | **$m**  | **$m**  | **$m**  | **Actual**  | **CER**  |
| **Gross profit** | **12390**  | **9**  | **7**  | **11**  | **12417**  | **12**  | **10**  |
| *- Gross Margin* | *82%*  |  |  |  | *82%*  | *-*  | *-*  |
| Distribution expense | (148) | -  | -  | -  | (148) | 2  | -  |
| R&D expense | (3663) | 33  | 79  | 1  | (3550) | 16  | 14  |
| *- R&D % of Total Revenue* | *24%*  |  |  |  | *23%*  | *-1pp*  | *-1pp*  |
| SG&A expense | (5085) | 37  | 1095  | 131  | (3822) | 6  | 4  |
| *- SG&A % of Total Revenue* | *33%*  |  |  |  | *25%*  | *+1pp*  | *+1pp*  |
| Total operating expense | (8896) | 70  | 1174  | 132  | (7520) | 10  | 9  |
| Other operating income & expense | 89  | -  | -  | 7  | 96  | >3x | >3x |
| **Operating profit** | **3583**  | **79**  | **1181**  | **150**  | **4993**  | **16**  | **13**  |
| *- Operating Margin* | *24%*  |  |  |  | *33%*  | *+1pp*  | *+1pp*  |
| Net finance expense | (349) | -  | -  | 44  | (305) | (7) | (9) |
| Taxation | (709) | (19) | (225) | (49) | (1002) | 33  | 30  |
| **EPS** | **$1.64**  | **$0.03**  | **$0.62**  | **$0.09**  | **$2.38**  | **14**  | **12**  |

---

 <u>Profit and Loss drivers</u>

Gross profit

The stable Gross Margin (Reported and Core) in 9M 2025 was a result of:

- Positive effects from geographic mix

- Negative effects from product mix. The rising contribution of Product Sales with profit sharing arrangements (*Lynparza*, *Enhertu*, *Tezspire*, *Koselugo*) has a negative impact on Gross Margin because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners. The profit share paid to partners is recorded in AstraZeneca's Cost of sales line

- Pricing adjustments, for example to sales reimbursed by the Medicare Part D programme in the US, diluted the Gross Margin

Variations in Gross Margin performance between periods can continue to be expected due to product seasonality, foreign exchange fluctuations, and other effects.

R&D expense

The change in R&D expense (Reported and Core) in the period was impacted by:

- Positive data read-outs for high-value pipeline opportunities that have ungated late-stage trials

- Investment in platforms, new technology and capabilities to enhance R&D capabilities

- Addition of R&D projects following completion of previously announced business development activity

SG&A expense

- The change in SG&A expense (Reported and Core) in the period was driven primarily by market development activities for launches and to support continued growth in existing brands

Other operating income and expense

- Other operating income in 9M 2025 consisted primarily of royalties and an upfront fee on a divestment

Net finance expense

Core Net finance expense decreased 4% (4% at CER) in 9M 2025, mainly driven by an adjustment of interest on tax, due to a reduction of tax liabilities relating to prior periods, recognised in the first quarter, and also a reduction in short-term borrowings.

Core Net finance expense decreased 7% (9% at CER) in Q3 2025, mainly driven by a reduction in short-term borrowings.

Taxation

The effective Reported and Core tax rates for the nine months to 30 September 2025 were 19% (9M 2024: 21% and 20% respectively).

The cash tax paid for the nine months ended 30 September 2025 was $2,193m (9M 2024: $1,978m), representing 22% of Reported Profit before tax (9M 2024: 28%).

 <u>Cash Flow</u>

Table 11: Cash Flow summary: 9M 2025

---

| | | | |
|:---|:---|:---|:---|
| For the **nine months** ended 30 September<br>| **2025** <br> **$m**  | **2024** <br> **$m**  | **Change$m**  |
| Reported Operating profit | 10765  | 7967  | 2798  |
| Depreciation, amortisation and impairment | 4222  | 4351  | (129) |
| Movement in working capital and short-term provisions | 64  | (543) | 607  |
| Gains on disposal of intangible assets | (118) | (34) | (84) |
| Fair value movements on contingent consideration arising from business combinations | (29) | 251  | (280) |
| Non-cash and other movements | 591  | 15  | 576  |
| Interest paid | (1069) | (1075) | 6  |
| Taxation paid | (2193) | (1978) | (215) |
| **Net cash inflow from operating activities** | **12233**  | **8954**  | **3279**  |
| **Net cash inflow before financing activities** | **6871**  | **2155**  | **4716**  |
| **Net cash (outflow) from financing activities** | **(4262)** | **(3325)** | **(937)** |

---

Net cash flow

The change in Net cash inflow from operating activities of $3,279m is primarily driven by the increased operating profit in 2025.

The change in Net cash inflow before financing activities of $4,716m is primarily driven by the reduction in cash outflow relating to the Acquisitions of subsidiaries, net of cash acquired of $2,771m, which in 2024 related to the acquisition of Gracell Biotechnologies Inc. and the acquisition of Fusion Pharmaceuticals Inc.

The change in Net cash outflow from financing activities of $937m is primarily driven by the issue of new long-term loans of $6,492m in 2024, with no issuance in 2025, and offset by the repayment of loans of $4,647m in 2024, with no repayment in 2025.

Capital expenditure

Capital expenditure on tangible assets and Software-related intangible assets amounted to $2,091m in 9M 2025 (9M 2024: $1,415m). The increase of capital expenditure in 2025 was driven by investment in several major manufacturing projects and continued investment in technology upgrades.

Net debt

Net debt decreased by $605m in the nine months to 30 September 2025 to $23,965m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Details of the Company's solicited credit ratings and further details on Net debt are disclosed in Note 3.

 <u>Net debt</u>

Table 12: Net debt summary

---

| | | | |
|:---|:---|:---|:---|
|  | **At 30 Sep 2025** <br> **$m**  | **At 31 Dec 2024** <br> **$m**  | **At 30 Sep 2024** <br> **$m**  |
| Cash and cash equivalents | 8143  | 5488  | 4797  |
| Other investments | 39  | 166  | 133  |
| **Cash and investments** | **8182**  | **5654**  | **4930**  |
| Overdrafts and short-term borrowings | (622) | (330) | (769) |
| Commercial paper | (1091) | -  | (472) |
| Lease liabilities | (1758) | (1452) | (1422) |
| Current instalments of loans | (4461) | (2007) | (12) |
| Non-current instalments of loans | (24700) | (26506) | (28887) |
| **Interest-bearing loans and borrowings (Gross debt)** | **(32632)** | **(30295)** | **(31562)** |
| Net derivatives | 485  | 71  | 284  |
| **Net debt** | **(23965)** | **(24570)** | **(26348)** |

---

Summarised financial information for guarantee of securities of subsidiaries

AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of 1.2% Notes due 2026, 4.8% Notes due 2027, 4.875% Notes due 2028, 1.75% Notes due 2028, 4.85% Notes due 2029, 4.9% Notes due 2030, 4.9% Notes due 2031, 2.25% Notes due 2031, 4.875% Notes due 2033 and 5% Notes due 2034 (the "AstraZeneca Finance USD Notes"). Each series of AstraZeneca Finance USD Notes has been fully and unconditionally guaranteed by AstraZeneca PLC. AstraZeneca Finance is 100% owned by AstraZeneca PLC and each of the guarantees issued by AstraZeneca PLC is full and unconditional and joint and several.

The AstraZeneca Finance USD Notes are senior unsecured obligations of AstraZeneca Finance and rank equally with all of AstraZeneca Finance's existing and future senior unsecured and unsubordinated indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca Finance USD Notes is the senior unsecured obligation of AstraZeneca PLC and ranks equally with all of AstraZeneca PLC's existing and future senior unsecured and unsubordinated indebtedness. Each guarantee by AstraZeneca PLC is effectively subordinated to any secured

indebtedness of AstraZeneca PLC to the extent of the value of the assets securing such indebtedness. The AstraZeneca Finance USD Notes are structurally subordinated to indebtedness and other liabilities of the subsidiaries of AstraZeneca PLC, none of which guarantee the AstraZeneca Finance USD Notes.

AstraZeneca PLC manages substantially all of its operations through divisions, branches and/or investments in subsidiaries and affiliates. Accordingly, the ability of AstraZeneca PLC to service its debt and guarantee obligations is also dependent upon the earnings of its subsidiaries, affiliates, branches and divisions, whether by dividends, distributions, loans or otherwise. Please refer to the Consolidated financial statements of AstraZeneca PLC in our Annual Report on Form 20-F as filed with the SEC and information contained herein for further financial information regarding AstraZeneca PLC and its consolidated subsidiaries. For further details, terms and conditions of the AstraZeneca Finance USD Notes please refer to AstraZeneca PLC's reports on Form 6-K furnished to the SEC on 22 February 2024, 3 March 2023 and 28 May 2021.

Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the Securities Act of 1933, as amended (the "Securities Act"), we present below the summary financial information for AstraZeneca PLC, as Guarantor, excluding its consolidated subsidiaries, and AstraZeneca Finance, as the issuer, excluding its consolidated subsidiaries. The following summary financial information of AstraZeneca PLC and AstraZeneca Finance is presented on a combined basis and transactions between the combining entities have been eliminated. Financial information for non-guarantor entities has been excluded. Intercompany balances and transactions between the obligor group and the non-obligor subsidiaries are presented on separate lines.

 <u>Obligor group summarised statements</u>

Table 13: Obligor group summarised Statement of comprehensive income: 9M 2025

---

| | | |
|:---|:---|:---|
| For the **nine months** ended 30 September<br>| **2025** <br> **$m**  | **2024** <br> **$m**  |
| Total Revenue | -  | -  |
| Gross profit  | -  | -  |
| Operating loss | -  | -  |
| Loss for the period | (957) | (894) |
| Transactions with subsidiaries that are not issuers or guarantors | 6509  | 1342  |

---

Table 14: Obligor group summarised Statement of financial position

---

| | | |
|:---|:---|:---|
|  | **At 30 Sep 2025** <br> **$m**  | **At 30 Sep 2024** <br> **$m**  |
| Current assets | 13  | 10  |
| Non-current assets | 141  | 84  |
| Current liabilities | (5976) | (801) |
| Non-current liabilities | (24704) | (28906) |
| Amounts due from subsidiaries that are not issuers or guarantors | 21519  | 16705  |
| Amounts due to subsidiaries that are not issuers or guarantors | -  | -  |

---

 <u>Capital allocation</u>

The Group's capital allocation priorities include: investing in the business and pipeline; maintaining a strong, investment-grade credit rating; potential value-enhancing business development opportunities; and supporting the progressive dividend policy.

In approving the declaration of dividends, the Board considers both the liquidity of the Company and the level of reserves legally available for distribution.

In FY 2025, the Company intends to increase the annual dividend per share declared to $3.20 per share. Dividends are paid to shareholders from AstraZeneca PLC, a Group holding company with no direct operations. The ability of AstraZeneca PLC to make shareholder distributions is dependent on the creation of profits for distribution and the receipt of funds from subsidiary companies.

The consolidated Group reserves set out in the Condensed consolidated statement of financial position do not reflect the profit available for distribution to the shareholders of AstraZeneca PLC.

In FY 2024, capital expenditure on tangible assets and Software-related intangible assets amounted to $2,218m. In FY 2025 the Group expects to increase expenditure on tangible assets and Software-related intangible assets by approximately 50%, driven by manufacturing expansion projects and investments in systems and technology.

 <u>Foreign exchange</u>

The Company's transactional currency exposures on working capital balances, which typically extend for up to three months, are hedged where practicable using forward foreign exchange contracts against the individual companies' reporting currency.Foreign exchange gains and losses on forward contracts transacted for transactional hedging are taken to profit or to Other comprehensive income if the contract is in a designated cashflow hedge.

In addition, the Company's external dividend payments, paid principally in pound sterling and Swedish krona, are fully hedged from the time of their announcement to the payment date.

Table 15: Currency sensitivities

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Currency** | **Primary Relevance** | **Exchange rate vs USD (average rate in period)** | **Exchange rate vs USD (average rate in period)** | **Exchange rate vs USD (average rate in period)** | **Exchange rate vs USD (average rate in period)** | **Exchange rate vs USD (average rate in period)** | **Annual impact of 5% weakening vs USD<sup>1</sup> ($m)** | **Annual impact of 5% weakening vs USD<sup>1</sup> ($m)** |
|  |  | **FY 2024<sup>2</sup>** | **YTD 2025<sup>3</sup>** | **Change** <br> **(%)** | **September 2025**<sup>4</sup> | **Change**<br> **(%)** | **TotalRevenue** | **Core Operating Profit** |
| EUR | Total Revenue | 0.92  | 0.89 | 3  | 0.85 | 8 | (461) | (232) |
| CNY | Total Revenue | 7.21  | 7.22 | - | 7.12 | 1 | (313) | (171) |
| JPY | Total Revenue | 151.46  | 148.10 | 2  | 147.87 | 2 | (179) | (121) |
| GBP | Operating expense | 0.78  | 0.76 | 3  | 0.74 | 6 | (68) | 124  |
| SEK | Operating expense | 10.57  | 9.94 | 6  | 9.37 | 13 | (9) | 69  |
| Other |  |  |  |  |  |  | (557) | (289) |

---

 *1. Assumes the average exchange rate vs USD in FY 2025 is 5% lower than the average rate in FY 2024. The impact data are estimates, based on best prevailing assumptions around currency profiles.*

 *2. Based on average daily spot rates 1 January 2024 to 31 December 2024.*

 *3. Based on average daily spot rates 1 January 2025 to 30 September 2025.*

 *4. Based on average daily spot rates 1 September 2025 to 30 September 2025.*

Interim financial statements

Table 16: Condensed consolidated statement of comprehensive income: 9M 2025

---

| | | |
|:---|:---|:---|
| For the **nine months** ended 30 September | **2025** <br> **$m**  | **2024** <br> **$m**  |
| *- Product Sales* | *41035*  | *37576*  |
| *- Alliance Revenue* | *2108*  | *1498*  |
| Product Revenue | 43143  | 39074  |
| Collaboration Revenue | 93  | 108  |
| **Total Revenue** | **43236**  | **39182**  |
| Cost of sales | (7515) | (7482) |
| **Gross profit** | **35721**  | **31700**  |
| Distribution expense | (426) | (412) |
| Research and development expense | (10370) | (8906) |
| Selling, general and administrative expense | (14441) | (14567) |
| Other operating income and expense | 281  | 152  |
| **Operating profit** | **10765**  | **7967**  |
| Finance income | 225  | 394  |
| Finance expense | (1210) | (1313) |
| Share of after tax losses in associates and joint ventures | (7) | (23) |
| **Profit before tax** | **9773**  | **7025**  |
| Taxation | (1869) | (1484) |
| **Profit for the period** | **7904**  | **5541**  |
| **Other comprehensive income** |  |  |
| **Items that will not be reclassified to profit or loss:** |  |  |
| Remeasurement of the defined benefit pension liability | 116  | 136  |
| Net (losses)/gains on equity investments measured at fair value through other comprehensive income | (21) | 264  |
| Fair value movements related to own credit risk on bonds designated as fair value through profit or loss | -  | 12  |
| Tax on items that will not be reclassified to profit or loss | (13) | (50) |
|  | **82**  | **362**  |
| **Items that may be reclassified subsequently to profit or loss:** |  |  |
| Foreign exchange arising on consolidation | 2266  | 543  |
| Foreign exchange arising on designated liabilities in net investment hedges | 15  | (84) |
| Fair value movements on cash flow hedges | 256  | (42) |
| Fair value movements on cash flow hedges transferred to profit and loss | (318) | 1  |
| Fair value movements on derivatives designated in net investment hedges | (7) | 13  |
| Gains of hedging | 8  | 2  |
| Tax on items that may be reclassified subsequently to profit or loss | (50) | 16  |
|  | **2170**  | **449**  |
| **Other comprehensive income, net of tax** | **2252**  | **811**  |
| **Total comprehensive income for the period** | **10156**  | **6352**  |
| **Profit attributable to:** |  |  |
| Owners of the Parent | 7899  | 5535  |
| Non-controlling interests | 5  | 6  |
|  | **7904**  | **5541**  |
| **Total comprehensive income attributable to:** |  |  |
| Owners of the Parent | 10149  | 6346  |
| Non-controlling interests | 7  | 6  |
|  | **10156**  | **6352**  |
|  ***Earnings per share*** |  |  |
| Basic earnings per $0.25 Ordinary Share | $5.10  | $3.57  |
| Diluted earnings per $0.25 Ordinary Share | $5.06  | $3.54  |
| Weighted average number of Ordinary Shares in issue (millions) | 1550  | 1550  |
| Diluted weighted average number of Ordinary Shares in issue (millions) | 1561  | 1562  |

---

Table 17: Condensed consolidated statement of comprehensive income: Q3 2025

---

| | | |
|:---|:---|:---|
| For the **quarter** ended 30 September<br>| **2025** <br> **$m**  | **2024** <br> **$m**  |
| *- Product Sales* | *14365*  | *12947*  |
| *- Alliance Revenue* | *815*  | *559*  |
| Product Revenue | 15180  | 13506  |
| Collaboration Revenue | 11  | 59  |
| **Total Revenue** | **15191**  | **13565**  |
| Cost of sales | (2801) | (3081) |
| **Gross profit** | **12390**  | **10484**  |
| Distribution expense | (148) | (145) |
| Research and development expense | (3663) | (3115) |
| Selling, general and administrative expense | (5085) | (5143) |
| Other operating income and expense | 89  | 25  |
| **Operating profit** | **3583**  | **2106**  |
| Finance income | 85  | 183  |
| Finance expense | (434) | (457) |
| Share of after tax losses in associates and joint ventures | 10  | (4) |
| **Profit before tax** | **3244**  | **1828**  |
| Taxation | (709) | (395) |
| **Profit for the period** | **2535**  | **1433**  |
| **Other comprehensive income** |  |  |
| **Items that will not be reclassified to profit or loss:** |  |  |
| Remeasurement of the defined benefit pension liability | 146  | 35  |
| Net gains on equity investments measured at fair value through other comprehensive income | 104  | 175  |
| Fair value movements related to own credit risk on bonds designated as fair value through profit or loss | -  | -  |
| Tax on items that will not be reclassified to profit or loss | (10) | (23) |
|  | **240**  | **187**  |
| **Items that may be reclassified subsequently to profit or loss:** |  |  |
| Foreign exchange arising on consolidation | (198) | 1097  |
| Foreign exchange arising on designated liabilities in net investment hedges | 5  | 12  |
| Fair value movements on cash flow hedges | (17) | 96  |
| Fair value movements on cash flow hedges transferred to profit and loss | (3) | (101) |
| Fair value movements on derivatives designated in net investment hedges | 13  | (32) |
| Costs of hedging | (2) | (12) |
| Tax on items that may be reclassified subsequently to profit or loss | 2  | (22) |
|  | **(200)** | **1038**  |
| **Other comprehensive income, net of tax** | **40**  | **1225**  |
| **Total comprehensive income for the period** | **2575**  | **2658**  |
| **Profit attributable to:** |  |  |
| Owners of the Parent | 2533  | 1429  |
| Non-controlling interests | 2  | 4  |
|  | **2535**  | **1433**  |
| **Total comprehensive income attributable to:** |  |  |
| Owners of the Parent | 2575  | 2654  |
| Non-controlling interests | -  | 4  |
|  | **2575**  | **2658**  |
|  ***Earnings per share*** |  |  |
| Basic earnings per $0.25 Ordinary Share | $1.64  | $0.92  |
| Diluted earnings per $0.25 Ordinary Share | $1.62  | $0.91  |
| Weighted average number of Ordinary Shares in issue (millions) | 1551  | 1550  |
| Diluted weighted average number of Ordinary Shares in issue (millions) | 1561  | 1562  |

---

Table 18: Condensed consolidated statement of financial position

---

| | | | |
|:---|:---|:---|:---|
| <br> **Assets** | **At30 Sep 2025**<br>**$m**  | **At31 Dec 2024**<br>**$m**  | **At30 Sep 2024**<br>**$m**  |
| **Non-current assets** |  |  |  |
| Property, plant and equipment | 12083  | 10252  | 10135  |
| Right-of-use assets | 1700  | 1395  | 1378  |
| Goodwill | 21219  | 21025  | 21139  |
| Intangible assets | 38191  | 37177  | 39394  |
| Investments in associates and joint ventures | 296  | 268  | 290  |
| Other investments | 1990  | 1632  | 1855  |
| Derivative financial instruments | 502  | 182  | 319  |
| Other receivables | 1159  | 930  | 915  |
| Income tax receivable | 1247  | -  | -  |
| Deferred tax assets | 6129  | 5347  | 5342  |
|  | **84516**  | **78208**  | **80767**  |
| **Current assets** |  |  |  |
| Inventories | 6593  | 5288  | 5662  |
| Trade and other receivables | 14338  | 12972  | 11879  |
| Other investments | 39  | 166  | 133  |
| Derivative financial instruments | 12  | 54  | 16  |
| Income tax receivable | 815  | 1859  | 1668  |
| Cash and cash equivalents | 8143  | 5488  | 4797  |
|  | **29940**  | **25827**  | **24155**  |
| **Total assets** | **114456**  | **104035**  | **104922**  |
| **Liabilities** |  |  |  |
| **Current liabilities** |  |  |  |
| Interest-bearing loans and borrowings | (6174) | (2337) | (1253) |
| Lease liabilities | (379) | (339) | (317) |
| Trade and other payables | (25028) | (22465) | (21684) |
| Derivative financial instruments | (29) | (50) | (17) |
| Provisions | (1176) | (1269) | (1187) |
| Income tax payable | (1268) | (1406) | (1468) |
|  | **(34054)** | **(27866)** | **(25926)** |
| **Non-current liabilities** |  |  |  |
| Interest-bearing loans and borrowings | (24700) | (26506) | (28887) |
| Lease liabilities | (1379) | (1113) | (1105) |
| Derivative financial instruments | -  | (115) | (34) |
| Deferred tax liabilities | (3604) | (3305) | (3568) |
| Retirement benefit obligations | (1271) | (1330) | (1361) |
| Provisions | (929) | (921) | (1063) |
| Income tax payable | (535) | (238) | (174) |
| Other payables | (2013) | (1770) | (1999) |
|  | **(34431)** | **(35298)** | **(38191)** |
| **Total liabilities** | **(68485)** | **(63164)** | **(64117)** |
| **Net assets** | **45971**  | **40871**  | **40805**  |
| **Equity** |  |  |  |
| Share capital | 388  | 388  | 388  |
| Share premium account | 35243  | 35226  | 35203  |
| Other reserves | 2044  | 2012  | 1990  |
| Retained earnings | 8213  | 3160  | 3138  |
| **Capital and reserves attributable to equity holders of the Parent** | **45888**  | **40786**  | **40719**  |
| Non-controlling interests | 83  | 85  | 86  |
| **Total equity** | **45971**  | **40871**  | **40805**  |

---

Table 19: Condensed consolidated statement of changes in equity

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Share capital**<br>**$m**  | **Share premium account**<br>**$m**  | **Other reserves**<br>**$m**  | **Retained earnings**<br>**$m**  | **Total attributable to owners of the parent**<br>**$m**  | **Non-controlling interests**<br>**$m**  | **Total equity**<br>**$m** |
| **At 1 Jan 2024** | **388**  | **35188**  | **2065**  | **1502**  | **39143**  | **23**  | **39166**  |
| Profit for the period | -  | -  | -  | 5535  | 5535  | 6  | 5541  |
| Other comprehensive income  | -  | -  | -  | 811  | 811  | -  | 811  |
| Transfer to other reserves | -  | -  | 1  | (1) | -  | -  | -  |
| **Transactions with owners** |  |  |  |  |  |  |  |
| Dividends | -  | -  | -  | (4602) | (4602) | -  | (4602) |
| Dividends paid to non-controlling interests | -  | -  | -  | -  | -  | (4) | (4) |
| Issue of Ordinary Shares | -  | 15  | -  | -  | 15  | -  | 15  |
| Changes in non-controlling interests | -  | -  | -  | -  | -  | 61  | 61  |
| Movement in shares held by Employee Benefit Trusts | -  | -  | (76) | -  | (76) | -  | (76) |
| Share-based payments charge for the period | -  | -  | -  | 487  | 487  | -  | 487  |
| Settlement of share plan awards | -  | -  | -  | (594) | (594) | -  | (594) |
| **Net movement** | **-**  | **15**  | **(75)** | **1636**  | **1576**  | **63**  | **1639**  |
| **At 30 September 2024** | **388**  | **35203**  | **1990**  | **3138**  | **40719**  | **86**  | **40805**  |
| **At 1 Jan 2025** | **388**  | **35226**  | **2012**  | **3160**  | **40786**  | **85**  | **40871**  |
| Profit for the period | -  | -  | -  | 7899  | 7899  | 5  | 7904  |
| Other comprehensive (expense)/income  | -  | -  | (61) | 2311  | 2250  | 2  | 2252  |
| Transfer to other reserves | -  | -  | 48  | (48) | -  | -  | -  |
| **Transactions with owners** |  |  |  |  |  |  |  |
| Dividends | -  | -  | -  | (4846) | (4846) | -  | (4846) |
| Dividends paid to non-controlling interests | -  | -  | -  | -  | -  | (2) | (2) |
| Issue of Ordinary Shares | -  | 17  | -  | -  | 17  | -  | 17  |
| Changes in non-controlling interests | -  | -  | -  | 8  | 8  | (7) | 1  |
| Movement in shares held by Employee Benefit Trusts | -  | -  | 45  | -  | 45  | -  | 45  |
| Share-based payments charge for the period | -  | -  | -  | 529  | 529  | -  | 529  |
| Settlement of share plan awards | -  | -  | -  | (800) | (800) | -  | (800) |
| **Net movement** | **-**  | **17**  | **32**  | **5053**  | **5102**  | **(2)** | **5100**  |
| **At 30 September 2025** | **388**  | **35243**  | **2044**  | **8213**  | **45888**  | **83**  | **45971**  |

---

Transfer to other reserves includes $70m in respect of the opening balance on the Cash flow hedge reserve. The cash flow hedge reserve was previously disclosed within Retained earnings but from 2025 is disclosed within Other reserves.

Table 20: Condensed consolidated statement of cash flows: 9M 2025

---

| | | |
|:---|:---|:---|
| For the **nine months** ended 30 September<br>| **2025** <br> **$m**  | **2024** <br> **$m**  |
| **Cash flows from operating activities** |  |  |
| Profit before tax | 9773  | 7025  |
| Finance income and expense | 985  | 919  |
| Share of after tax losses of associates and joint ventures | 7  | 23  |
| Depreciation, amortisation and impairment | 4222  | 4351  |
| Movement in working capital and short-term provisions | 64  | (543) |
| Gains on disposal of intangible assets | (118) | (34) |
| Fair value movements on contingent consideration arising from business combinations | (29) | 251  |
| Non-cash and other movements | 591  | 15  |
| **Cash generated from operations** | **15495**  | **12007**  |
| Interest paid | (1069) | (1075) |
| Tax paid | (2193) | (1978) |
| **Net cash inflow from operating activities** | **12233**  | **8954**  |
| **Cash flows from investing activities** |  |  |
| Acquisition of subsidiaries, net of cash acquired | (60) | (2771) |
| Payment of contingent consideration from business combinations | (897) | (737) |
| Purchase of property, plant and equipment | (1774) | (1216) |
| Disposal of property, plant and equipment | 10  | 53  |
| Purchase of intangible assets | (2844) | (2415) |
| Disposal of intangible assets | 96  | 107  |
| Purchase of non-current asset investments | (218) | (96) |
| Disposal of non-current asset investments | -  | 73  |
| Movement in short-term investments, fixed deposits and other investing instruments | 122  | 67  |
| Payments to associates and joint ventures | (10) | (158) |
| Disposal of investments in associates and joint ventures | -  | 13  |
| Interest received | 213  | 281  |
| **Net cash outflow from investing activities** | **(5362)** | **(6799)** |
| **Net cash inflow before financing activities** | **6871**  | **2155**  |
| **Cash flows from financing activities** |  |  |
| Proceeds from issue of share capital | 17  | 15  |
| Own shares purchased by Employee Benefit Trust | (508) | (81) |
| Payments to acquire non-controlling interests | (14) | -  |
| Issue of loans and borrowings | 9  | 6492  |
| Repayment of loans and borrowings | (20) | (4647) |
| Dividends paid | (4968) | (4626) |
| Hedge contracts relating to dividend payments | 113  | 16  |
| Repayment of obligations under leases | (273) | (233) |
| Movement in short-term borrowings | 1382  | 572  |
| Payment of Acerta Pharma share purchase liability | -  | (833) |
| **Net cash outflow from financing activities** | **(4262)** | **(3325)** |
| Net increase/(decrease) in Cash and cash equivalents in the period | 2609  | (1170) |
| Cash and cash equivalents at the beginning of the period | 5429  | 5637  |
| Exchange rate effects | 42  | (32) |
| **Cash and cash equivalents at the end of the period** | **8080**  | **4435**  |
| **Cash and cash equivalents consist of:** |  |  |
| Cash and cash equivalents | 8143  | 4797  |
| Overdrafts | (63) | (362) |
|  | **8080**  | **4435**  |

---

Notes to the Interim financial statements

 <u>Note 1: Basis of preparation and accounting policies</u>

These unaudited Interim financial statements for the nine months ended 30 September 2025 have been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting' (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom's Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards.

The unaudited Interim financial statements for the nine months ended 30 September 2025 were approved by the Board of Directors for publication on 6 November 2025.

This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2024 were prepared in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group's published consolidated financial statements for the year ended 31 December 2024.

The comparative figures for the financial year ended 31 December 2024 are not the Group's statutory accounts for that financial year. Those accounts have been reported on by the Group's auditors and have been delivered to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.

Product Revenue

Effective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal 'Product Revenue' representing the summation of Product Sales and Alliance Revenue.

Product Revenue and Collaboration Revenue form Total Revenue.

Product Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue.

Full descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group's <u>Annual Report and Form 20-F Information 2024</u>.

There are no changes to the Revenue accounting policy regarding the types of transactions recorded in each revenue category. The comparative period has been retrospectively adjusted to reflect the additional subtotal, resulting in total Product Revenue being reported for the nine months ended 30 September 2024 of $39,074m.

Going concern

The Group has considerable financial resources available. As at 30 September 2025, the Group has $13.0bn in financial resources (cash and cash equivalent balances of $8.1bn and undrawn committed bank facilities of $4.9bn that are available until April 2030), with $6.6bn of borrowings due within one year. These facilities contain no financial covenants.

The Group has assessed the prospects of the Group over a period longer than the required 12 months from the date of Board approval of these consolidated financial statements, with no deterioration noted requiring a further extension of this review. The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas.

Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements.

Legal proceedings

The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group's <u>Annual Report and Form 20-F Information 2024</u>.

 <u>Note 2: Intangible assets</u>

The acquisition of EsoBiotec completed on 19 May 2025. The transaction is recorded as an asset acquisition based upon the concentration test permitted under IFRS 3 'Business Combinations', with consideration and net assets acquired of $403m, which included intangible assets acquired of $426m, current payables of $29m, $4m of cash and cash equivalents and current receivables of $2m. Contingent consideration of up to $575m could be paid on achievement of regulatory milestones, those liabilities will be recorded when the relevant regulatory milestone is achieved.

Intangible asset additions of $536m in the quarter relate to the total of net upfront payment made, the present value of non-contingent future payments and a sales-related payment due to Merck in connection with the restructuring of arrangements relating to *Koselugo*, recorded as an asset acquisition. A regulatory milestone of $50m, and sales-related payment of $35m additionally fell due and were capitalised in the quarter. Further contingent payments of up to $300m could be paid on achievement of regulatory milestones or on achievement of sales-related thresholds. Those liabilities

will be recorded when milestones are triggered, or performance conditions have been satisfied. Sales-related payments are accrued and capitalised when considered probable with reference to the latest Group sales forecasts for approved indications at the present value of expected future cash flows.

 <u>Note 3: Net debt</u>

Table 21: Net debt

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **At 1 Jan 2025** <br>**$m**  | **Cash flow** <br>**$m**  | **Acquisitions**<br>**$m** | **Non-cash** <br> **and other** <br>**$m**  | **Exchange** <br> **movements** <br>**$m**  | **At 30 Sep 2025** <br>**$m**  |
| Non-current instalments of loans | (26506) | -  | -  | 2433  | (627) | (24700) |
| Non-current instalments of leases | (1113) | -  | -  | (217) | (49) | (1379) |
| **Total long-term debt** | **(27619)** | **-**  | **-**  | **2216**  | **(676)** | **(26079)** |
| Current instalments of loans | (2007) | 11  | -  | (2465) | -  | (4461) |
| Current instalments of leases | (339) | 326  | (1) | (346) | (19) | (379) |
| Commercial paper | -  | (1091) | -  | -  | -  | (1091) |
| Collateral received from derivative counterparties | (181) | (232) | -  | -  | -  | (413) |
| Other short-term borrowings excluding overdrafts | (90) | (59) | -  | -  | 3  | (146) |
| Overdrafts | (59) | (3) | -  | -  | (1) | (63) |
| **Total current debt** | **(2676)** | **(1048)** | **(1)** | **(2811)** | **(17)** | **(6553)** |
| **Gross borrowings** | **(30295)** | **(1048)** | **(1)** | **(595)** | **(693)** | **(32632)** |
| Net derivative financial instruments | 71  | (385) | -  | 799  | -  | 485  |
| **Net borrowings** | **(30224)** | **(1433)** | **(1)** | **204**  | **(693)** | **(32147)** |
| Cash and cash equivalents | 5488  | 2492  | 120  | -  | 43  | 8143  |
| Other investments - current | 166  | (122) | -  | -  | (5) | 39  |
| **Cash and investments** | **5654**  | **2370**  | **120**  | **-**  | **38**  | **8182**  |
| **Net debt** | **(24570)** | **937**  | **119**  | **204**  | **(655)** | **(23965)** |

---

The table above provides an analysis of Net debt and a reconciliation of Net cash flow to the movement in Net debt. The Group monitors Net debt as part of its capital management policy as described in Note 28 of the <u>Annual Report and Form 20-F Information 2024</u>. Net debt is a non-GAAP financial measure.

Net debt decreased by $605m in the nine months to 30 September 2025 to $23,965m.

Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Non-cash movements in the period include fair value adjustments under IFRS 9 'Financial Instruments'.

The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 September 2025 was $413m (31 December 2024: $181m) and the carrying value of such cash collateral posted by the Group at 30 September 2025 was $25m (31 December 2024: $129m).

The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown.

During the nine months ended 30 September 2025, Moody's upgraded the Group's solicited long term credit rating to A1 from A2, which occurred during Q1 2025. The short-term rating remained at P-1. There were no changes to Standard and Poor's credit ratings (long term: A+; short term: A-1).

 <u>Note 4: Financial Instruments</u>

As detailed in the Group's most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, lease liabilities and interest-bearing loans and borrowings.

The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are held at $539m (31 December 2024: $353m) and for which a fair value loss of $47m has been recognised in the nine months ended 30 September 2025 (9M 2024: $nil). In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusted as necessary for impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains and/or losses that are presented in Net gains/(losses) on equity investments measured at fair value through other comprehensive income, in the Condensed consolidated statement of comprehensive income for the nine months ended 30 September 2025 are Level 1 fair value measurements, valued based on quoted prices in active markets.

Financial instruments measured at fair value include $2,004m of other investments, $6,732m held in money-market funds and $485m of derivatives as at 30 September 2025. With the exception of derivatives being Level 2 fair valued, and certain equity instruments of $539m categorised as Level 3, the aforementioned balances are Level 1 fair valued. Financial instruments measured at amortised cost include $25m of cash collateral pledged to counterparties. The total fair value of Interest-bearing loans and borrowings as at 30 September 2025, which have a carrying value of $32,632m in the Condensed consolidated statement of financial position, was $32,275m.

Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues.

The contingent consideration balance relating to BMS's share of the global diabetes alliance of $523m (31 December 2024: $1,309m) would increase/decrease by $52m with an increase/decrease in sales of 10%, as compared with the current estimates.

Table 22: Contingent consideration

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | **2025** | |
|  | **Diabetes alliance** <br> **$m**  | **Other** <br> **$m**  | **Total** <br> **$m**  | **2024** <br>**Total** <br> **$m**  |
| **At 1 January** | **1309** | **442** | **1751** | **2137** |
| Additions through business combinations | -  | -  | -  | 198  |
| Settlements | (787) | (110) | (897) | (737) |
| Revaluations | (30) | 1  | (29) | 252  |
| Discount unwind | 31  | 15  | 46  | 85  |
| **At 30 September** | **523** | **348** | **871** | **1935** |

---

 <u>Note 5: Legal proceedings and contingent liabilities</u>

AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices.

The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2024 and the Interim Financial Statements for the six months ended 30 June 2025 (the Disclosures). Information about the nature and facts of the cases is disclosed in accordance with IAS 37 'Provisions, Contingent Liabilities and Contingent Assets'.

As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain.

In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein.

AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP.

 <u>Matters disclosed in respect of the third quarter of 2025 and to 6 November 2025</u>

Table 23: Patent litigation

Legal proceedings brought against AstraZeneca

---

| | |
|:---|:---|
| **Factor Bioscience patent proceedings, US**<br> *Considered to be a contingent liability* | ∗In September 2025, Factor Bioscience Inc. (Factor) filed a complaint against AstraZeneca, and others in the U.S. District Court for the District of Delaware, alleging infringement of several Factor patents related to technology for producing gene-edited cells using synthetic messenger ribonucleic acid (mRNA) molecules encoding transcription activator-like effector nuclease (TALEN) gene-editing proteins. <br> ∗The complaint alleges that certain drug research, design and development activities by AstraZeneca and others infringe Factor's patents.  |
| ***Forxiga* patent proceedings, UK**<br> *Matter concluded* | ∗In the UK, one of AstraZeneca's patents relating to *Forxiga* was challenged by Generics (UK) Limited, Teva Pharmaceutical Industries Limited, and Glenmark Pharmaceuticals Europe Limited.<br> ∗Trial regarding patent validity occurred in March 2025. In April 2025, the UK Patents Court held the patent invalid. AstraZeneca appealed the decision. In July 2025, the UK Court of Appeal dismissed AstraZeneca's appeal and upheld the lower court's invalidity decision. AstraZeneca's application for permission to appeal to the UK Supreme Court was denied.<br> ∗In March 2025 and onward, AstraZeneca obtained injunctions against generic manufacturers' at-risk sales of dapagliflozin products in the UK. All injunctions have since been lifted.<br> ∗This matter has concluded. |

---

Legal proceedings brought by AstraZeneca

---

| | |
|:---|:---|
| ***Lynparza* patent proceedings, Canada**<br> *Considered to be a contingent asset* | ∗In July 2025, AstraZeneca was served with a Notice of Allegation from Cipla Ltd. challenging a patent relating to *Lynparza*.<br> ∗AstraZeneca commenced an action in response in August 2025. Trial is scheduled to begin in April 2027.<br> ∗In August 2025, AstraZeneca was served with a Notice of Allegation from Natco Pharma (Canada) Inc. challenging a patent relating to *Lynparza*.<br> ∗AstraZeneca commenced an action in response in October 2025. No trial date has been set. |
| ***Soliris* patent proceedings, UK**<br> *Considered to be a contingent asset* | ∗In May 2024, AstraZeneca initiated patent infringement proceedings against Amgen Ltd. and Samsung Bioepis UK Limited (Samsung) in the UK High Court of Justice alleging that their respective biosimilar eculizumab products infringe an AstraZeneca patent; on the same day, Samsung initiated a revocation action for the same patent.<br> ∗Trial was held in March 2025. In May 2025, the UK court issued a decision finding AstraZeneca's patent invalid and not infringed.<br> ∗In August 2025, AstraZeneca appealed. |
| ***Tagrisso* patent proceedings, Russia**<br> *Considered to be a contingent asset* | ∗In August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow region (Court) against the Russian Ministry of Health (MOH) and Axelpharm LLC (Axelpharm) for improper use of AstraZeneca's information in the authorisation of a generic version of *Tagrisso*. The suit against the MOH was dismissed in July 2024, after two appeals. The case against Axelpharm was dismissed in September 2024, and AstraZeneca has appealed.<br> ∗In November 2023, Axelpharm sought a compulsory licence under a patent related to *Tagrisso*; the action remains pending. The Axelpharm patent on which the compulsory licensing action was based was held invalid by the Russian Patent and Trademark Office (PTO) in August 2024 following a challenge by AstraZeneca. The PTO's decision was upheld in June 2025, following an appeal by Axelpharm. In August 2025, Axelpharm filed a further appeal before the Presidium of the Intellectual Property Court and that appeal will be heard in November 2025.<br> ∗In July 2024, AstraZeneca filed a patent infringement claim against Axelpharm in relation to a generic version of *Tagrisso*. The action was stayed by the Court pending resolution of the compulsory licensing action.<br> ∗In August 2024, after AstraZeneca filed a complaint, the Federal Anti-Monopoly Service of Russia (FAS) initiated a case against Axelpharm and OncoTarget LLC (OncoTarget). In November 2024, the FAS found Axelpharm to have committed unfair competition, but not OncoTarget. Axelpharm's appeal against the FAS's finding was upheld in June 2025. AstraZeneca appealed against the ruling in June 2025 and a hearing has been scheduled before the Ninth Arbitration Appellate Court in December 2025.  |

---

Table 24: Commercial litigation

Legal proceedings brought against AstraZeneca

---

| | |
|:---|:---|
| **340B Antitrust litigation, US**<br> *Considered to be a contingent liability* | ∗In September 2021, AstraZeneca was served with a class-action antitrust complaint filed in the US District Court for the Western District of New York (District Court) by Mosaic Health alleging a conspiracy to restrict access to 340B discounts in the diabetes market through contract pharmacies.<br> ∗In September 2022, the District Court granted AstraZeneca's motion to dismiss the complaint. In February 2024, the District Court denied Plaintiffs' request to file an amended complaint and entered an order closing the matter. In March 2024, Plaintiffs filed an appeal.<br> ∗In August 2025, the US Court of Appeals for the Second Circuit reversed the District Court's decision.<br> ∗AstraZeneca and the other defendants have filed a motion for reconsideration. |
| ***Seroquel XR* Antitrust Litigation, US**<br> *Matter concluded* | ∗In 2019, AstraZeneca was named in several related complaints now proceeding in US District Court in Delaware (District Court), including several putative class action lawsuits that were purportedly brought on behalf of classes of direct purchasers or end payors of *Seroquel XR*, that allege AstraZeneca and generic drug manufacturers violated US antitrust laws when settling patent litigation related to *Seroquel XR*.<br> ∗In July 2022, the District Court dismissed claims relating to one of the generic manufacturers while allowing claims relating to the second generic manufacturer to proceed.<br> ∗In September 2024, AstraZeneca reached a settlement agreement with one of the plaintiff classes which the court approved.<br> ∗In May 2025, AstraZeneca resolved the matter with all remaining plaintiffs for a total payment of $97m. In September of 2025, the Court approved the class-related portion of the settlement.<br> ∗The matter is now concluded. |

---

Table 25: Government investigations and proceedings

Legal proceedings brought against AstraZeneca

---

| | |
|:---|:---|
| **Shenzhen Bay Customs Office, China**<br> *Considered to be a contingent liability*<br>| ∗In relation to the alleged unpaid importation taxes, in October 2025, AstraZeneca received a final appraisal notice, which supersedes the previously-disclosed appraisal notices, from the Shenzhen Bay Customs Office stating that the total amount of unpaid tax, inclusive of the previously-disclosed amounts, is RMB 24 million (approximately $3.5m).<br> ∗To the best of AstraZeneca's knowledge, the importation taxes referred to in the appraisal notice relate to *Enhertu*, *Imfinzi* and *Imjudo*.<br> ∗AstraZeneca has since prepaid the full amount as voluntary compensation to the State. <br> ∗A fine of between one and five times the amount of these paid importation taxes may also be levied if AstraZeneca is found liable. |

---

Legal proceedings brought by AstraZeneca

---

| | |
|:---|:---|
| **340B State litigation, US**<br> *Considered to be a contingent asset* | ∗AstraZeneca has filed lawsuits against Arkansas, Colorado, Hawaii, Kansas, Louisiana, Maine, Maryland, Minnesota, Mississippi, Missouri, Nebraska, North Dakota, Oklahoma, South Dakota, Tennessee, Utah, and West Virginia challenging the constitutionality of each state's 340B statute.<br> ∗In Arkansas, AstraZeneca moved for summary judgment in August 2025, and the Court denied the intervenor's motion to dismiss in September 2025 finding AstraZeneca's claims were distinct from the claims in the prior PhRMA litigation. Trial is scheduled for February 2026.<br> ∗In Colorado, AstraZeneca filed a complaint in August 2025 and a motion for a preliminary injunction in October 2025.<br> ∗In Hawaii, AstraZeneca filed a complaint in August 2025 and a motion for a preliminary injunction in September 2025.<br> ∗In Louisiana, the Louisiana Department of Justice sent AstraZeneca a Civil Investigative Demand in September 2025 for alleged non-compliance with Louisiana's 340B Statute.<br> ∗In Maine, AstraZeneca filed a complaint in September 2025. <br> ∗In North Dakota, AstraZeneca filed a complaint in August 2025. <br> ∗In Oklahoma, AstraZeneca filed a complaint and a motion for a preliminary injunction in October 2025. Later in October, the court granted AstraZeneca's motion for a preliminary injunction.<br> ∗In South Dakota, AstraZeneca filed a complaint in August 2025. <br> ∗In Tennessee, AstraZeneca filed a complaint in August 2025.  |
| **Inflation Reduction Act Litigation, US**<br> *Considered to be a contingent asset* | ∗In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS' motions and dismissed AstraZeneca's lawsuit.<br> ∗In May 2025, the US Court of Appeals for the Third Circuit affirmed the District Court's dismissal of AstraZeneca's challenge.<br> ∗In September 2025, AstraZeneca sought review by the US Supreme Court. |

---

Other

Additional government inquiries

As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters.

 <u>Note 6: Subsequent events</u>

On 22 October 2025, AstraZeneca, by exercise of an option, completed the acquisition of the remaining share capital of SixPeaks Bio AG (SixPeaks), following an initial investment of $15m made in Q2 2024. $170m was paid on closing, $30m to be paid after two years and up to a further $100m is payable on achievement of regulatory milestones, which will be accrued for at its present value. These payments will be recognised in equity as SixPeaks has been consolidated as a subsidiary due to AstraZeneca's control since the initial equity investment in Q2 2024.

 <u>Note 7: Analysis of Revenue and Other operating income and expense</u>

Table 26: Product Sales year-on-year analysis: 9M 2025

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| For the **nine months** | **World** | **World** | **World** | **US** | **US** | **Emerging Markets** | **Emerging Markets** | **Emerging Markets** | **Europe** | **Europe** | **Europe** | **Established RoW** | **Established RoW** | **Established RoW** |
| ended 30 September |  | **Change** | **Change** |  | **Change** |  | **Change** | **Change** |  | **Change** | **Change** |  | **Change** | **Change** |
|  | **$m**  | **Act %**  | **CER %**  | **$m**  | **Act %**  | **$m**  | **Act %**  | **CER %**  | **$m**  | **Act %**  | **CER %**  | **$m**  | **Act %**  | **CER %**  |
| *Tagrisso* | 5352  | 10  | 10  | 2222  | 11  | 1509  | 11  | 13  | 1030  | 8  | 5  | 591  | 5  | 5  |
| *Imfinzi* | 4317  | 25  | 25  | 2484  | 32  | 463  | 27  | 33  | 879  | 26  | 24  | 491  | (6) | (7) |
| *Calquence* | 2551  | 10  | 10  | 1702  | 5  | 164  | 41  | 48  | 569  | 16  | 14  | 116  | 18  | 20  |
| *Lynparza* | 2401  | 8  | 7  | 1054  | 10  | 487  | 2  | 4  | 667  | 9  | 7  | 193  | 3  | 3  |
| *Enhertu* | 685  | 73  | 76  | -  | -  | 476  | 84  | 90  | 146  | 59  | 56  | 63  | 34  | 38  |
| *Zoladex* | 852  | 4  | 6  | 13  | 17  | 661  | 6  | 9  | 112  | 1  | (1) | 66  | (10) | (9) |
| *Truqap* | 495  | 85 | 85 | 413  | 59  | 16  | n/m | n/m | 45  | n/m | n/m | 21  | n/m | n/m |
| *Imjudo* | 253  | 22  | 21  | 165  | 23  | 17  | 56  | 60  | 36  | 37  | 35  | 35  | (5) | (6) |
| Other Oncology | 322  | (10) | (9) | 6  | (60) | 215  | (7) | (5) | 15  | (13) | (15) | 86  | (7) | (9) |
| **Oncology** | **17228**  | **15**  | **15**  | **8059**  | **17**  | **4008**  | **16**  | **19**  | **3499**  | **17**  | **14**  | **1662**  | **3**  | **2**  |
| *Farxiga* | 6341  | 11  | 11  | 1244  | (3) | 2623  | 18  | 21  | 2147  | 13  | 10  | 327  | 3  | 3  |
| *Crestor* | 941  | 5  | 6  | 36  | 9  | 808  | 11  | 12  | 1  | (98) | (98) | 96  | (5) | (6) |
| *Brilinta* | 665  | (33) | (33) | 326  | (40) | 203  | (13) | (12) | 129  | (36) | (37) | 7  | (46) | (44) |
| *Lokelma* | 517  | 32  | 31  | 226  | 25  | 99  | 47  | 49  | 91  | 37  | 34  | 101  | 30  | 28  |
| *Seloken* | 468  | 1  | 3  | -  | n/m | 451  | -  | 3  | 14  | 44  | 41  | 3  | (5) | (2) |
| Roxadustat | 227  | (12) | (11) | -  | -  | 227  | (12) | (11) | -  | -  | -  | -  | -  | -  |
| *Wainua* | 143  | n/m | n/m | 137  | n/m | 4  | -  | -  | 2  | -  | -  | -  | -  | -  |
| Other CVRM | 418  | (24) | (24) | 44  | (69) | 208  | 12  | 13  | 119  | (31) | (31) | 47  | (9) | (10) |
| **CVRM** | **9720**  | **4**  | **5**  | **2013**  | **(9)** | **4623**  | **12**  | **14**  | **2503**  | **5**  | **3**  | **581**  | **3**  | **2**  |
| *Symbicort* | 2180  | (1) | -  | 903  | 2  | 624  | (4) | (3) | 406  | (2) | (4) | 247  | 3  | 5  |
| *Fasenra* | 1451  | 19  | 19  | 886  | 18  | 81  | 18  | 22  | 351  | 19  | 17  | 133  | 26  | 27  |
| *Breztri* | 906  | 26  | 26  | 462  | 26  | 239  | 20  | 21  | 136  | 34  | 31  | 69  | 31  | 31  |
| *Tezspire* | 317  | 89  | 87  | -  | -  | 24  | n/m | n/m | 207  | 98  | 93  | 86  | 55  | 55  |
| *Pulmicort* | 357  | (31) | (30) | 4  | (74) | 280  | (34) | (33) | 46  | (10) | (11) | 27  | 3  | 5  |
| *Saphnelo* | 483  | 48  | 47  | 421  | 43  | 10  | 98  | 99  | 34  | 97  | 92  | 18  | 61  | 58  |
| *Airsupra* | 115  | n/m | n/m | 113  | n/m | 2  | n/m | n/m | -  | -  | -  | -  | -  | -  |
| Other R&I | 211  | (13) | (13) | 67  | -  | 95  | (26) | (25) | 44  | 3  | 1  | 5  | (5) | (3) |
| **R&I** | **6020**  | **11**  | **11**  | **2856**  | **18**  | **1355**  | **(9)** | **(7)** | **1224**  | **19**  | **17**  | **585**  | **18**  | **19**  |
| *Beyfortus* | 222  | 18  | 19  | 137  | (8) | -  | -  | -  | 83  | n/m | n/m | 2  | n/m | n/m |
| *Synagis* | 220  | (36) | (35) | (2) | 9  | 160  | (5) | (1) | 37  | (54) | (54) | 25  | (75) | (75) |
| *FluMist* | 132  | 21  | 19  | 20  | (23) | 1  | n/m | n/m | 82  | 34  | 30  | 29  | 34  | 35  |
| Other V&I | -  | n/m | n/m | -  | -  | -  | n/m | n/m | -  | n/m | n/m | -  | n/m | n/m |
| **V&I** | **574**  | **(16)** | **(15)** | **155**  | **(23)** | **161**  | **(4)** | **-**  | **202**  | **7**  | **5**  | **56**  | **(54)** | **(54)** |
| *Ultomiris* | 3453  | 22  | 21  | 1961  | 20  | 177  | 92  | n/m | 769  | 18  | 16  | 546  | 17  | 16  |
| *Soliris* | 1436  | (30) | (28) | 844  | (28) | 327  | (11) | (2) | 159  | (54) | (55) | 106  | (35) | (34) |
| *Strensiq* | 1188  | 19  | 19  | 953  | 17  | 61  | 58  | 61  | 89  | 22  | 19  | 85  | 23  | 21  |
| *Koselugo* | 498  | 36  | 34  | 157  | -  | 188  | 75  | 70  | 115  | 56  | 53  | 38  | 36  | 35  |
| Other Rare Disease | 177  | 18  | 18  | 83  | 15  | 37  | 54  | 57  | 50  | 6  | 4  | 7  | 13  | 12  |
| **Rare Disease** | **6752**  | **6**  | **6**  | **3998**  | **4**  | **790**  | **26**  | **32**  | **1182**  | **(1)** | **(3)** | **782**  | **7**  | **6**  |
| *Nexium* | 626  | (7) | (5) | 53  | (30) | 476  | 4  | 6  | 31  | (22) | (24) | 66  | (31) | (31) |
| Other | 115  | (26) | (25) | (4) | n/m | 88  | (17) | (16) | 27  | (23) | (22) | 4  | 37  | 28  |
| **Other Medicines** | **741**  | **(10)** | **(9)** | **49**  | **(43)** | **564**  | **-**  | **2**  | **58**  | **(23)** | **(23)** | **70**  | **(29)** | **(29)** |
| **Total Medicines** | **41035**  | **9**  | **9**  | **17130**  | **10**  | **11501**  | **10**  | **13**  | **8668**  | **10**  | **8**  | **3736**  | **3**  | **3**  |

---

 *The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.*

Table 27: Product Sales year-on-year analysis: Q3 2025

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| For the **quarter** | **World** | **World** | **World** | **US** | **US** | **Emerging Markets** | **Emerging Markets** | **Emerging Markets** | **Europe** | **Europe** | **Europe** | **Established RoW** | **Established RoW** | **Established RoW** |
| ended 30 September |  | **Change** | **Change** |  | **Change** |  | **Change** | **Change** |  | **Change** | **Change** |  | **Change** | **Change** |
|  | **$m**  | **Act %**  | **CER %**  | **$m**  | **Act %**  | **$m**  | **Act %**  | **CER %**  | **$m**  | **Act %**  | **CER %**  | **$m**  | **Act %**  | **CER %**  |
| *Tagrisso* | 1864  | 11  | 10  | 784  | 10  | 501  | 12  | 12  | 372  | 13  | 7  | 207  | 11  | 8  |
| *Imfinzi* | 1601  | 33  | 31  | 912  | 34  | 169  | 41  | 44  | 342  | 45  | 37  | 178  | 6  | 3  |
| *Calquence* | 916  | 13  | 11  | 612  | 7  | 61  | 49  | 45  | 200  | 19  | 12  | 43  | 29  | 30  |
| *Lynparza* | 837  | 7  | 5  | 365  | 5  | 164  | 6  | 4  | 242  | 13  | 7  | 66  | 7  | 5  |
| *Enhertu* | 257  | 73  | 75  | -  | -  | 184  | 89  | 94  | 52  | 50  | 44  | 21  | 30  | 32  |
| *Zoladex* | 285  | 7  | 6  | 4  | 21  | 219  | 6  | 7  | 40  | 20  | 13  | 22  | (8) | (9) |
| *Truqap* | 193  | 55  | 54  | 159  | 33  | 7  | n/m | n/m | 18  | n/m | n/m | 9  | n/m | n/m |
| *Imjudo* | 84  | 16  | 14  | 55  | 18  | 6  | 52  | 45  | 13  | 29  | 21  | 10  | (13) | (16) |
| Other Oncology | 106  | (9) | (10) | 2  | (52) | 69  | (7) | (7) | 5  | (6) | (11) | 30  | (9) | (12) |
| **Oncology** | **6143**  | **18**  | **17**  | **2893**  | **16**  | **1380**  | **21**  | **21**  | **1284**  | **24**  | **17**  | **586**  | **9**  | **7**  |
| *Farxiga* | 2134  | 10  | 8  | 441  | 7  | 893  | 19  | 18  | 698  | 4  | (2) | 102  | (4) | (5) |
| *Crestor* | 305  | 1  | (1) | 12  | 5  | 262  | 4  | 3  | -  | n/m | n/m | 31  | 2  | (1) |
| *Brilinta* | 146  | (55) | (56) | 55  | (71) | 66  | -  | (1) | 23  | (66) | (68) | 2  | (59) | (62) |
| *Lokelma* | 189  | 32  | 30  | 82  | 25  | 36  | 42  | 41  | 35  | 39  | 31  | 36  | 37  | 32  |
| *Seloken* | 160  | 6  | 6  | -  | n/m | 153  | 5  | 5  | 6  | 62  | 47  | 1  | 3  | 5  |
| Roxadustat | 77  | (17) | (18) | -  | -  | 77  | (17) | (18) | -  | -  | -  | -  | -  | -  |
| *Wainua* | 59  | n/m | n/m | 55  | n/m | 3  | -  | -  | 1  | -  | -  | -  | -  | -  |
| Other CVRM | 144  | (18) | (19) | 17  | (56) | 69  | 8  | 8  | 43  | (15) | (18) | 15  | (32) | (34) |
| **CVRM** | **3214**  | **2**  | **-**  | **662**  | **(10)** | **1559**  | **12**  | **11**  | **806**  | **(2)** | **(8)** | **187**  | **(2)** | **(4)** |
| *Symbicort* | 742  | 5  | 4  | 305  | 5  | 224  | 10  | 10  | 135  | 4  | (2) | 78  | (5) | (4) |
| *Fasenra* | 530  | 22  | 20  | 330  | 21  | 28  | 5  | 7  | 122  | 20  | 13  | 50  | 41  | 39  |
| *Breztri* | 323  | 21  | 20  | 167  | 17  | 83  | 22  | 20  | 49  | 33  | 25  | 24  | 24  | 23  |
| *Tezspire* | 119  | 75  | 66  | -  | -  | 8  | n/m | n/m | 79  | 82  | 70  | 32  | 47  | 43  |
| *Pulmicort* | 93  | (33) | (35) | -  | n/m | 72  | (34) | (36) | 12  | (15) | (19) | 9  | (6) | (6) |
| *Saphnelo* | 180  | 45  | 44  | 156  | 42  | 4  | 8  | 5  | 13  | 83  | 72  | 7  | 94  | 83  |
| *Airsupra* | 45  | n/m | n/m | 43  | n/m | 2  | n/m | n/m | -  | -  | -  | -  | -  | -  |
| Other R&I | 53  | (26) | (26) | 12  | (12) | 24  | (43) | (42) | 15  | 15  | 9  | 2  | (8) | (8) |
| **R&I** | **2085**  | **14**  | **12**  | **1013**  | **19**  | **445**  | **(3)** | **(3)** | **425**  | **23**  | **16**  | **202**  | **16**  | **15**  |
| *Beyfortus* | 94  | (30) | (29) | 35  | (63) | -  | -  | -  | 59  | 53  | 53  | -  | -  | -  |
| *Synagis* | 58  | (37) | (40) | (1) | n/m | 39  | 6  | 4  | 11  | (14) | (24) | 9  | (80) | (80) |
| *FluMist* | 122  | 21  | 20  | 20  | (12) | 1  | n/m | n/m | 82  | 46  | 42  | 19  | (12) | (11) |
| Other V&I | -  | n/m | n/m | -  | n/m | -  | -  | -  | -  | n/m | n/m | -  | -  | -  |
| **V&I** | **274**  | **(23)** | **(24)** | **54**  | **(63)** | **40**  | **7**  | **7**  | **152**  | **41**  | **37**  | **28**  | **(57)** | **(57)** |
| *Ultomiris* | 1225  | 19  | 17  | 690  | 16  | 64  | n/m | n/m | 271  | 14  | 8  | 200  | 18  | 15  |
| *Soliris* | 462  | (24) | (24) | 276  | (24) | 102  | (8) | (5) | 47  | (46) | (49) | 37  | (24) | (24) |
| *Strensiq* | 441  | 29  | 28  | 369  | 29  | 11  | 45  | 38  | 32  | 26  | 18  | 29  | 21  | 17  |
| *Koselugo* | 224  | 88  | 79  | 51  | (7) | 113  | n/m | n/m | 44  | 53  | 44  | 16  | 55  | 52  |
| Other Rare Disease | 64  | 31  | 26  | 29  | 14  | 17  | n/m | n/m | 16  | (5) | (10) | 2  | 20  | 16  |
| **Rare Disease** | **2416**  | **12**  | **11**  | **1415**  | **7**  | **307**  | **76**  | **73**  | **410**  | **4**  | **(2)** | **284**  | **12**  | **9**  |
| *Nexium* | 200  | (5) | (5) | 16  | (45) | 143  | 2  | 3  | 14  | 1  | (3) | 27  | (4) | (6) |
| Other | 33  | (39) | (38) | (7) | n/m | 29  | (26) | (26) | 9  | 7  | 13  | 2  | n/m | n/m |
| **Other Medicines** | **233**  | **(12)** | **(12)** | **9**  | **(73)** | **172**  | **(4)** | **(3)** | **23**  | **4**  | **3**  | **29**  | **-**  | **(4)** |
| **Total Medicines** | **14365**  | **11**  | **9**  | **6046**  | **8**  | **3903**  | **15**  | **15**  | **3100**  | **14**  | **7**  | **1316**  | **5**  | **3**  |

---

 *The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.*

Table 28: Alliance Revenue: 9M 2025

---

| | | |
|:---|:---|:---|
| For the **nine months** ended 30 September | **2025** <br> **$m**  | **2024** <br> **$m**  |
| *Enhertu* | 1291  | 1045  |
| *Tezspire* | 453  | 303  |
| *Beyfortus* | 252  | 75  |
| *Datroway* | 38  | -  |
| Other Alliance Revenue | 74  | 75  |
| **Total** | **2108**  | **1498**  |

---

Table 29: Collaboration Revenue: 9M 2025

---

| | | |
|:---|:---|:---|
| For the **nine months** ended 30 September | **2025** <br> **$m**  | **2024** <br> **$m**  |
| *Farxiga*: sales milestones | 81  | 52  |
| *Beyfortus*: sales milestones | -  | 56  |
| Other Collaboration Revenue | 12  | -  |
| **Total** | **93**  | **108**  |

---

Table 30: Other operating income and expense: 9M 2025

---

| | | |
|:---|:---|:---|
| For the **nine months** ended 30 September | **2025** <br> **$m**  | **2024** <br> **$m**  |
| **Total** | **281**  | **152**  |

---

Other shareholder information

Financial calendar

Announcement of FY and Q4 2025 results: 10 February 2026

Dividend payment dates

Dividends are normally paid as follows:

First interim: Announced with the half year results and paid in September

Second interim: Announced with the full year results and paid in March

Contact details

For Investor Relations contacts, <u>click here</u>. For Media contacts, <u>click here</u>.

Addresses for correspondence

---

| | | | |
|:---|:---|:---|:---|
| **Registered office** | **Registrar andtransfer office\*** | **Swedish Central Securities Depository** | **US depositary**<br>|
| 1 Francis Crick Avenue<br> Cambridge Biomedical Campus<br> Cambridge<br> CB2 0AA | Equiniti Limited<br> Aspect House<br> Spencer Road<br> Lancing<br> West Sussex<br> BN99 6DA | Euroclear Sweden AB<br> PO Box 191<br> SE-101 23 Stockholm | J.P. Morgan Chase Bank N.A.EQ Shareowner Services<br> P.O. Box 64504<br> St. Paul<br> MN 55164-0504<br>|
| UK | UK | Sweden | US |
| +44 (0) 20 3749 5000 | 0800 389 1580 (UK only) | +46 (0) 8 402 9000 | +1 (888) 697 8018 (US only) |
|  | +44 (0) 121 415 7033 |  | +1 (651) 453 2128 |

---

\* A change of registrar will take effect on Monday, 17th November 2025. Computershare Investor Services PLC will be appointed as the new registrar, replacing Equiniti Limited. Shareholders can contact Computershare by phone on 0370 707 1682 (from inside the UK) or +44 (0) 370 707 1682 (from outside the UK) between 8:30 a.m. to 5:30 p.m. (GMT), Monday to Friday (excluding public holidays in England and Wales) alternatively, via email web.queries@computershare.co.uk .

Trademarks

Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies other than AstraZeneca that appear in this document include: *Beyfortus*, a trademark of Sanofi Pasteur Inc.; *Enhertu* and *Datroway,* trademarks of Daiichi Sankyo; *Seloken*, owned by AstraZeneca or Taiyo Pharma Co., Ltd (depending on geography); *Synagis*, owned by AstraZeneca or Sobi aka Swedish Orphan Biovitrum AB (publ). (depending on geography); and *Tezspire*, a trademark of Amgen, Inc.

Information on or accessible through AstraZeneca's websites, including <u>astrazeneca.com</u>, does not form part of and is not incorporated into this announcement.

 <u>AstraZeneca</u>

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit <u>astrazeneca.com</u> and follow the Company on Social Media <u>@AstraZeneca</u>.

 <u>Cautionary statements regarding forward-looking statements</u>

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things:

- the risk of failure or delay in delivery of pipeline or launch of new medicines;

- the risk of failure to meet regulatory or ethical requirements for medicine development or approval;

- the risk of failures or delays in the quality or execution of the Group's commercial strategies;

- the risk of pricing, affordability, access and competitive pressures;

- the risk of failure to maintain supply of compliant, quality medicines;

- the risk of illegal trade in the Group's medicines;

- the impact of reliance on third-party goods and services;

- the risk of failure in information technology or cybersecurity;

- the risk of failure of critical processes;

- the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives;

- the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce;

- the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment;

- the risk of the safety and efficacy of marketed medicines being questioned;

- the risk of adverse outcome of litigation and/or governmental investigations;

- intellectual property risks related to the Group's products;

- the risk of failure to achieve strategic plans or meet targets or expectations;

- the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business;

- the risk of failure in internal control, financial reporting or the occurrence of fraud; and

- the risk of unexpected deterioration in the Group's financial position.

Glossary

1L, 2L, etc first line, second line, etc

aHUS Atypical haemolytic uraemic syndrome

BCG Bacillus Calmette-Guérin therapy

BRCA / m Breast cancer gene / mutation

BTC Biliary tract cancer

BTKi Bruton tyrosine kinase inhibitor

CER Constant exchange rates

CHMP Committee for Medicinal Products for Human Use (EU)

CI Confidence interval

CKD Chronic kidney disease

CLL Chronic lymphocytic leukaemia

CN China

COPD Chronic obstructive pulmonary disease

CRSwNP Chronic rhinosinusitis with nasal polyps

CTx Chemotherapy

CVRM Cardiovascular, Renal and Metabolism

EBITDA Earnings before interest, tax, depreciation and amortisation

EGFR / m Epidermal growth factor receptor gene / mutation

EGPA Eosinophilic granulomatosis with polyangiitis

EPS Earnings per share

ESC European Society of Cardiology

ESMO European Society for Medical Oncology

EVH Extravascular haemolysis

FDC Fixed dose combination

FLOT Fluorouracil, oxaliplatin and docetaxel

GEJ Gastro oesophageal junction

GI Gastrointestinal

GLP-1 glucagon-like peptide-1 receptor

gMG Generalised myasthenia gravis

HCC Hepatocellular carcinoma

HER2 / +/- /low /m Human epidermal growth factor receptor 2 gene / positive / negative / low expression / gene mutant

HES Hyper-eosinophilic syndrome

HF/ pEF / rEF Heart failure / with preserved ejection fraction / with reduced ejection fraction

HR / + / - Hormone receptor / positive / negative

IASLC International Association for the Study of Lung Cancer

ICS Inhaled corticosteroid

IHC Immunohistochemistry

IL-5 Interleukin-5

IO Immuno-oncology

ISH In situ hybridization

JP Japan

LABA Long-acting beta-agonist

LAMA Long-acting muscarinic-agonist

mBC Metastatic breast cancer

MCL Mantle cell lymphoma

mCRPC Metastatic castration-resistant prostate cancer

MEK An enzyme that drives NF1-PN disease

MG-ADL Myasthenia Gravis Activities of Daily Living

n/m Growth rate not meaningful

NF1-PN Neurofibromatosis type 1 plexiform neurofibromas

NMOSD Neuromyelitis optica spectrum disorder

NRDL National reimbursement drug list

NSCLC Non-small cell lung cancer

OS Overall survival

PARP Poly ADP ribose polymerase

pCR Pathologic complete response

PCSK9 Proprotein convertase subtilisin/kexin type 9

pMMR proficient mismatch repair

PNH Paroxysmal nocturnal haemoglobinuria

PTEN Phosphatase and tensin homologue gene

QMG Quantitative Myasthenia Gravis

ROW Rest of world

SBP systolic blood pressure

sBRCAm Somatic breast cancer gene mutation

SGLT2 Sodium-glucose cotransporter 2

SLE Systemic lupus erythematosus

T-DM1 Ado-trastuzumab emtansine

THP A treatment regimen: docetaxel, trastuzumab and pertuzumab

TNBC Triple negative breast cancer

WCLC World Conference on Lung Cancer

 <u>SIGNATURES</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 06 November 2025

---

| |
|:---|
| By: /s/ Matthew Bowden |
| Name: Matthew Bowden |
| Title: Company Secretary |

---